DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO DECLARE FOR USE IN THE INFORMATION EXCHANGE

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2 (i)		✓
A, part 2 (ii)		
A, part 2 (iii)		
B (i)		
B (ii)		
C		
D		
E		
F		✓
G		

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 15 April 2008

State Party to the Convention: Australia

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1]*

Exchange of data on research centres and laboratories[1]

Australia's submission regarding questions 1-7 of Form A, part 1 is at **Attachment 1.1 to 1.5**, below.

1. Name(s) of facility[2] _____

2. Responsible public or private organization or company _____
_____

3. Location and postal address _____
_____
_____
_____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

_____

5. Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)

_____

6. If no maximum containment unit, indicate highest level of protection

_____

7. Scope and general description of activities, including type(s) of microorganisms and/or toxins as appropriate

_____
_____
_____

[1]The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
[2]For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
[3]In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1]*

Exchange of data on research centres and laboratories

Background Information

Australia has four maximum containment units which meet the criteria for a "maximum containment laboratory" as specified in the 1983 WHO Laboratory Biosafety Manual.

They are:

- The Australian Animal Health Laboratory (**Attachment 1.2**)
- The National High Security Quarantine Laboratory (**Attachment 1.3**)
- The Queensland Health Forensic and Scientific Services Virology Laboratory (**Attachment 1.4**)
- The Emerging Infectious Diseases and Biohazard Response Unit (**Attachment 1.5)**

Data on these facilities relating to questions 1 to 7 of Form A, Part 1 are provided below in accordance with the Annex to the Final Declaration on Confidence Building Measures.

The Emerging Infectious Diseases and Biohazard Response Unit is operated by the Institute of Clinical Pathology and Medical Research (ICPMR) at Westmead in New South Wales. During 2007 the PC3+ high containment facility at the ICPMR was upgraded to the highest containment level, PC4.

The National High Security Laboratory (NHSQL) operates under the auspices of the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne. In 2007 additional maximum containment laboratory facilities are being established at VIDRL that will boost capability for responding to a terrorist attack involving bioagents. In addition, some Australian hospitals and university departments have lower level containment units where diagnostic and research work is conducted.

On 13 April 2007, the Council of Australian Governments (COAG) considered the recommendations of the *Report on the Regulation and Control of Biological Agents* (the COAG Report) and agreed to the establishment of a national regulatory scheme for biological agents of security concern.

The COAG Report's recommendations encompass:

- the development of a national authority to oversee the regulatory scheme - a section within the Department of Health and Ageing has been established to fulfil this role;
- the development of legislation: the *National Health Security (NHS) Act 2007*, which was passed by Parliament on 20 September 2007 and given Royal Assent on 28 September 2007, fulfils this role;
- establishment of a National Register (informed by mandatory reporting) identifying entities handling SSBA and allowing for the provision of this information to intelligence agencies [the *NHS Act 2007* provides the legislative basis for the National Register];
- the development of a registration scheme addressing physical, personnel and transport security concerns and including a security audit and inspection process; and
- the delivery of an education and awareness-raising campaign covering the proposed security requirements, use of the National Register, and coordination with other existing schemes.

The COAG Report also recommended the establishment of a two-tiered list of security-sensitive biological agents (SSBA). There are 22 SSBA on the list recommended by COAG—12 on Tier 1 (agents of the highest security concern) and 10 on Tier 2 (agents of high security concern). Tier 1 agents will be regulated from January 2009 with Tier 2 agents being regulated from January 2010. The regulatory measures proposed by this review are proportional to the risk posed by agents on the list.

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1]*

Exchange of data on research centres and laboratories

1. Name of facility

Australian Animal Health Laboratory

2. Responsible public or private organisation/ company

Commonwealth Scientific and Industrial Research Organisation (Federal Government) and the Department of Agriculture, Fisheries and Forestry (Federal Government). Note: Australia has a two-tiered system of Government, with the Federal Government and, to a lesser extent, the six respective State Governments and two Territories all involved in the formulation and implementation of Government policy.

3. Location and postal address

Location	Postal address
5 Port Arlington Road Geelong, Victoria AUSTRALIA	PO Bag 24 Geelong VIC 3220 AUSTRALIA

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. The AAHL is funded by the Australian Government, via CSIRO and the Department of Agriculture, Fisheries and Forestry. It is also funded by industry organisations and commercial companies.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m^2)

One maximum containment system and enclosure. Total floor space 11,000m^2 , comprising three main parts: a large-animal accommodation area, total floor area about 3,500 m^2 made up of 29 rooms – each of these with a floor area of about 24 m^2 – and with a service area, incinerator, and autopsy area.

A laboratory complex of total floor area about 3,500 m^2 made up of three functional laboratory suites – each of these with a floor area of about 1,100 m^2 – and each comprised of six laboratories and four attached small-animal rooms. The laboratory suites are for diagnosis, pathology and virology. There are attached service areas.

A common support area for glass washing, tissue culture, laundry and other services.

6. If no maximum containment unit, indicate highest level of protection

N/A

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1 continued]*

Exchange of data on research centres and laboratories

7. Scope and general description of activities, including type(s) of microorganisms and/or toxins as appropriate.

The AAHL plays a vital role in maintaining Australia's capability to quickly diagnose exotic (foreign) and emerging animal diseases. This is achieved through ongoing research programs to develop the most sensitive, accurate and timely diagnostic tests, which are critical to the success of any eradication campaign in the event of a disease outbreak.

AAHL also undertakes research to develop new diagnostic tests, vaccines and treatments for endemic animal diseases of national importance. Major diseases of livestock, aquaculture animals, and wildlife, are studied. AAHL includes a high-biocontainment facility, to safely fulfil its major role of diagnosing emergency animal disease outbreaks.

The laboratory is a World Animal Health Organisation reference laboratory for avian influenza, Newcastle disease, bluetongue disease, and epizootic haematopoietic necrosis virus (EHNV). The AAHL is also an OIE Collaborating Centre for New and Emerging Diseases, a WHO Collaborating Centre for Severe Acute Respiratory Syndrome (SARS), and a national reference laboratory for rabies and brucella.

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1 continued]*

Exchange of data on research centres and laboratories

1. Name of facility

National High Security Quarantine Laboratory (NHSQL)

2. Responsible public or private organisation/company:

Department of Health and Ageing (Commonwealth Government), Department of Human Services (State government).

3. Location and postal address:

Location	Postal address
Victorian Infectious Diseases Reference Laboratory 10 Wreckyn Street North Melbourne Victoria AUSTRALIA	National High Security Quarantine Laboratory c/o VIDRL Locked Bag 815 Carlton South VIC 3053 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. It receives funding from Commonwealth and State Departments of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m^2)

One high security laboratory, containing two portable isolation units. Total area 90m2.

6. If no maximum containment unit, indicate highest level of protection

N/A

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The diagnosis of possible imported cases of viral haemorrhagic fever or other quarantinable viral diseases such as yellow fever. Development of laboratory tests and protocols for exotic respiratory viral diseases, including *influenzavirus* A/H5N1 ('bird flu') and SARS. In addition, VIDRL has established and maintained the capability to perform diagnostic testing for the *variolavirus*. See also, background information at Attachment 1.1.

Attachment 1.4

CONFIDENCE BUILDING MEASURE A (Part 1) *[Form A, part 1 continued]*

Exchange of data on research centres and laboratories

1. Name of facility

Queensland Health and Forensic Scientific Services (QHFSS).

2. Responsible public or private organisation/company:

Queensland Department of Health (State Government).

3. Location and postal address:

Location	Postal address
39 Kessels Road Coopers Plains Queensland AUSTRALIA	PO Box 594 Archerfield QLD 4108 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. It receives funding from Commonwealth and State Departments of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)

Two. Total area 150m^2.

If no maximum containment unit, indicate highest level of protection

N/A.

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The maximum containment facility at QHFSS, a state government public health virology laboratory, has both a diagnostic and a research function. The maximum containment facilities are used for the development and performance of diagnostic tests on patients with suspected exotic or endemic viral illness. This includes Hendra virus or exotic haemorrhagic fever viruses. The only PC4 level pathogens that the laboratory has are Hendra virus and SARS coronavirus, which are used for diagnostic purposes. The laboratory intends to introduce reagents useful for the diagnosis of a number of exotic viral diseases including Ebola, Lassa, Junin, Rift Valley fevers and Hantavirus among others. These reagents will consist of either inactivated diagnostic reagents, cloned viral subunits or live virus.

No research involving PC4 level organisms was conducted in the facility in 2007. Hendra virus was isolated from a horse in 2007.

Attachment 1.5

Exchange of data on research centres and laboratories

1.	Name(s) of facility	Emerging Infectious Diseases and Biohazard Response Unit (EIBRU).
2.	Responsible public or private organization or company	Institute for Clinical Pathology and Medical Research, Sydney West Area Health Service.
3.	Location and postal address	Centre for Infectious Diseases and Microbiology Laboratory Services (CIDMLS) ICPMR Institute Road. Westmead NSW 2145

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

   Funded by New South Wales Department of Health

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m^2)

   One maximum containment PC4 unit—Laboratory work area 85.5m^2

6. If no maximum containment unit, indicate highest level of protection

   N/A

7. Scope and general description of activities, including type(s) of microorganisms and/or toxins as appropriate

   Laboratory investigation of human specimens or substances suspected of containing an exotic agent, emerging infectious disease or bioterrorism agent such as pandemic influenza, anthrax and ricin toxin for the state of New South Wales.

CONFIDENCE BUILDING MEASURE A (Part 2(i)) *[Form A, part 2(i)]*

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes. Australia has a science and technology program in defence against biological agents, which occurs in the Defence Science and Technology Organisation (DSTO), Department of Defence, as detailed below (see Form A, Part 2(ii)).

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

CONFIDENCE BUILDING MEASURE A (Part 2(ii)) *[Form A, part 2(ii)]*

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The objective of the program is to provide the Australian Government with an appropriate understanding of the issues pertinent to protection against biological weapons. The program also assists in the provision of a defensive capability for the Australian Defence Force (ADF) and contributes to Defence support to the civil power in the management of biological threats to the community. The program enhances the ability of the ADF to operate in parts of the world where biological weapons might be used. It also enhances Australia's ability to contribute to biological arms control verification. The principal research activities are concerned with the detection and analysis of biological species that have been identified as potential biological warfare agents and development of medical countermeasures to those agents. The program also covers toxins that are considered threats in terms of both the Biological and Chemical Weapons Conventions.

2. State the total funding for the programme and its source.

The program is funded solely by the Australian Department of Defence, with an allocation for the current financial year (July 2007-June 2008) of approximately $2 652 000.

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes. Work is contracted to non-defence facilities.

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

For the calendar year 2007, the following payments were made;

- $125 000 to James Cook University
- $62 000 to the Cooperative Research Centre (CRC) for Diagnostics.
- $15 000 to CSIRO Australian Animal Health Laboratories part of the Cooperative Research Centre (CRC) for Biosecurity

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

The James Cook University of Technology funding is to support a post doctoral fellow to undertake investigations into the causative organism of the disease Q-Fever. This work is to be completed in June 2008 however, depending on progress, there will be further consideration of another 2-3 years.

In a collaborative research project, DSTO and CSIRO are examining the neutralizing capacity of mesophase nanomaterials to bind the plant toxin ricin. Completion date expected to be 30 June 2008.

The program includes an association with the CRC - Diagnostics that aims to produce high affinity reagents that can be used in the treatment or detection of biological agents. This interaction is through the funding of two PhD students, one located at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) - Health Science and Nutrition, Parkville, Victoria, and the other at LaTrobe, University, Bundoora, Victoria.

The funding to CSIRO Australian Animal Health Laboratories supports a DSTO employee undertaking doctoral studies in developing detection methods for uncharacterised viruses.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

The organisational structure is as follows. There is a single active research cell operating within the Department of Defence within the hierarchy represented below.

Defence Department
▽
Defence Science and Technology Organisation
▽
Platforms and Human Sciences
▽
Human Protection and Performance Division
▽
Biological Defence Research

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

See Form A, Part 2(iii) and the associated attachment (**Attachment 2**) for Australia's response.

CONFIDENCE BUILDING MEASURE A (Part 2(iii)) *[Form A, part 2(iii)]*

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

Australia's submission of Form A, Part 2 (iii) is at **Attachment 2**.

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
2. Where is it located (include both address and geographical location)?
3. Floor area of laboratory areas by containment level:

   BL2 _____ (sqM)

   BL3 _____ (sqM)

   BL4 _____ (sqM)

   Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.

   (I) Total number of personnel _____

   (ii) Division of personnel:

   Military _____

   Civilian _____

   (iii) Division of personnel by category:

   Scientists _____

   Engineers _____

   Technicians _____

   Administration and support staff _____

   (iv) List the scientific disciplines represented in the scientific/ engineering staff.

   (v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research _____

Development _____

Test and evaluation _____

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of microorganisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

*Including viruses and prions.

Attachment 2

CONFIDENCE BUILDING MEASURE A (Part 2(iii)) *[Form A, part 2(iii)]*

National biological defence research and development programme

Facilities

Australia has one facility that meets the criteria of paragraph 7 in Form A, part 2 (ii).

1. **Name**

Human Protection and Performance Division, DSTO

2. Location

Location	Postal address
506 Lorimer Street Fishermans Bend Victoria AUSTRALIA	Platforms Sciences Laboratory (PSL) 506 Lorimer Street Fishermans Bend Victoria AUSTRALIA

3. Floor Area

BL2	150 square metres
BL3	60
BL4	nil

4. Personnel

(i) Total of 25 staff years effort for the combined biological defence and arms control programs, with contributions from 33 personnel.
(ii) All are civilian.
(iii) 32 scientists, 1 technician, nil engineers, shared administrative and support staff.
(iv) Biochemistry, molecular biology, microbiology, immunology, chemistry, pharmacology, physicists.
(v) Yes—there are two PhD students working as contractors on this program at the facility.
(vi) Currently wholly financed by the Department of Defence, there is expected to be other funding in the 2006-2007 financial year from the Department of Health and Ageing, Emergency Management Australia and Australia Post, amounts are as yet unknown.
(vii) Research funded at ca. $2 385 000 per annum.
(viii) Publication in scientific journals is encouraged, and staff are expected to maintain their professional status by such publication.
(ix) The publications are listed at **Attachment 4** (see Form C).

5. Description of Biological Defence Work

Various types of work are undertaken, as outlined in the following sections:

CONFIDENCE BUILDING MEASURE A (Part 2(iii)) *[Form A, part 2(iii) continued]*

(1) Detection of biological entities recognised as potential biological warfare agents

Immunological and gene based techniques for rapid identification of BW agents are being investigated.

Recombinant and colostrum derived antibodies, and combinatorial peptides are being produced to a number of BW agents, including *B. pseudomallei*, *Bacillus anthracis*, anthrax toxins and ricin. Platforms for the amplification of antibody avidity, such as self-assembling gels, are also being investigated. Binding inhibition and cytotoxicity assays are being developed to assess the usefulness of potential therapeutic agents such as antibodies, peptides and aptamers.

PCR assays for the rapid detection of potential BW agents. Current research focuses on the evaluation of diagnostic tools that enable rapid detection of microbial antibiotic resistance and genetically manipulated bacteria.

(2) Physical methods for rapid detection of bio-aerosols

Methods of particle characterisation for provision of rapid warning of a bio-aerosol are being assessed.

(3) Treatment/Toxicology

Cultured human lung cells are being developed as a test bed for examining potential therapeutic compounds against toxin agents. Compounds for treatment of ricin intoxication are currently being examined.

A program for the development of DNA vaccines against selected agents is being pursued.

(4) Detection of biological toxins using physico-chemical methods

Studies on detection of biological material using mass spectrometry and other physico-chemical methods are being conducted to determine their utility for field detection of biological toxins and BWC verification procedures. This work has included the analysis of ricin and crude extracts of ricin by MALDI and FT-ICR mass spectrometry.

(5) Strengthening the Biological Weapons Convention (BWC)

A BWC Regional Workshop, co-hosted by Australia and Indonesia, was convened in 2007 to help BWC States Parties in South East Asia become better engaged with the Geneva-based intersessional program of work as a means to reduce the possibility of bioterrorism in the region, or the inadvertent assistance by states in the region to biological weapons programs being developed elsewhere. This workshop was followed up by more specialised regional workshops on biosafety and biosecurity.

CONFIDENCE BUILDING MEASURE B(i) *[Form B(i)]*

Background information on outbreaks of reportable infectious diseases

In 2006, Australia had no outbreaks of infectious diseases and similar occurrences caused by toxins that deviate from the normal pattern. For this reason, we report the information requested in Form B(i) with respect to diseases of humans (see **Attachment 3.1**), animals (see **Attachment 3.2**) and plants (see **Attachment 3.3)**, but make no formal report regarding the information requested in Form B(ii). We provide, however, information relevant to Form B(ii) regarding animal plant diseases in Attachments 3.2 and 3.3, respectively.

Attachment 3.1

CONFIDENCE BUILDING MEASURE B(i) *[Form B(i)]*

Background information on outbreaks of reportable infectious diseases

In accordance with the requirements agreed at the Third Review Conference, a summary table of notifiable diseases for Australia for the years 2000 to 2007 is attached as Form B (i).

(A) Human diseases

The Australian Government Department of Health and Ageing has overall responsibility for national disease surveillance. The Department's Office of Health Protection routinely receives diagnostic data from key medical laboratories throughout Australia.

Each Australian State and Territory has legislation which requires doctors, hospitals and/or laboratories to report the occurrence of certain diseases, known as "notifiable diseases". Under the auspices of the Communicable Diseases Network of Australia (the Network), the State and Territory health authorities provide data on an agreed set of notifiable diseases to the Australian Government Department of Health and Ageing. The data are collated by the Department and published quarterly in the *Communicable Diseases Intelligence* and updated three times per week on the Department's website (www.health.gov.au/cda). *Communicable Diseases Intelligence* is sent to the World Health Organization and to approximately 1,100 health professionals and researchers both nationally and internationally as well as published on the Department website.

The Network meets fortnightly by teleconference. It provides a forum for information exchange on communicable disease activity in Australia and New Zealand and enables Federal and State health authorities to cooperate in taking prompt action to control outbreaks.

No. of cases of Nationally Notifiable Communicable Diseases in Humans, 2000 to 2007

Disease	2000	2001	2002	2003	2004	2005	2006	2007*
AIDS	206	261	208	225	222	160	NA	NA
HIV	714	755	765	848	861	886	NA	NA
Anthrax	NN	0	0	0	0	0	1	1
Barmah Forest virus infection	646	1142	910	1367	1105	1323	2122	1701
Botulism	2	2		1	1	3	1	1
Brucellosis	29	20	40	20	38	41	50	40
Campylobacteriosis	13669	16131	14732	15361	15579	16492	15406	17677
Congenital Rubella	0	0	2	3	1	1	0	1
Congenital Syphilis	5	21	18	13	13	15	13	9
Chancroid	1	0	0	NN	NN	NN	NN	NN
Chlamydial (NEC)	16963	20325	24459	30439	36224	41376	47243	51458
Cholera	2	4	5	1	5	3	3	3
Cryptosporidiosis	1152	1629	3273	1223	1684	3212	3205	2877

CONFIDENCE BUILDING MEASURE B(i) *[Form B(i) continued]*

Disease	2000	2001	2002	2003	2004	2005	2006	2007*
Dengue	198	131	170	861	351	221	188	322
Diphtheria	0	1	0	0	0	0	0	0
Donovanosis	22	32	17	16	10	13	6	3
Flavivirus NEC	67	87	73	60	61	27	32	23
Gonococcal infection	5893	6287	6440	6790	7183	8084	8592	7622
Haemolytic uraemic syndrome	17	3	13	15	16	20	13	20
Haemophilus influenzae type b	27	20	31	19	15	17	22	17
Hepatitis (NEC)	1	3	0	0	0	0	1	0
Hepatitis A	816	539	392	431	319	327	280	164
Hepatitis B (incident)	415	421	392	348	283	251	293	290
Hepatitis B (unspecified)	7767	8035	6673	5814	5788	6327	6244	7520
Hepatitis C (incident)	535	693	452	520	453	376	437	354
Hepatitis C (unspecified)	19688	19433	15611	13680	12726	12009	11994	13034
Hepatitis D	28	20	22	27	29	30	31	34
Hepatitis E	12	14	12	12	28	30	24	18
Hydatid infection	4	NN	NN	NN	NN	NN	NN	NN
Influenza (laboratory confirmed)	104	1293	3669	3481	2136	4565	3258	10703
Japanese encephalitis	0	0	0	1	1			
Kunjin virus	4	5		18	12	1	3	1
Legionellosis	470	311	315	333	312	331	350	313
Leprosy	4	10	6	5	7	10	5	12
Leptospirosis	239	246	160	126	177	129	147	106
Listeriosis	67	64	62	69	67	54	61	50
Malaria	967	717	468	592	557	822	771	578
Measles	110	141	32	93	45	10	125	11
Meningococcal infection	628	686	689	558	405	392	317	311
Mumps	212	116	69	77	102	241	275	584
Murray Valley encephalitis	16	6	2	0	1	2	1	0
Ornithosis	102	137	213	200	239	164	171	97
Pertussis	5981	9510	5564	5096	8757	11201	10997	5472
Pneumococcal disease (invasive)	538	1762	2441	2232	2370	1745	1453	1498
Q fever	574	693	795	560	464	353	407	458
Ross River virus infection	4224	3227	1459	3850	4209	2544	5490	4183
Rubella	322	264	253	54	31	31	59	36
Salmonellosis (NEC)	6194	7053	7880	7011	7844	8425	8255	9725
Shigellosis	491	567	507	442	520	729	545	618

CONFIDENCE BUILDING MEASURE B(i) *[Form B(i) continued]*

Disease	2000	2001	2002	2003	2004	2005	2006	2007*
SLTEC/VTEC	43	46	59	52	49	86	70	111
Syphilis	2101	1830	2013	2005	138	1	42	49
Syphilis - Infectious	177	251	359	453	622	641	830	1291
Syphilis - duration more than 2 years	1,602	1,135	1,084	1,204	1583	1598	1819	1793
Tetanus	8	3	4	4	5	2	3	3
Tuberculosis	1520	1430	1131	1048	1138	1083	1193	1131
Typhoid	58	75	69	51	76	52	77	91

NA - not available
NN - not nationally notifiable in that year
NEC - Not Elsewhere Classified
* 2007 provisional figures only

Information relevant to Measure B(ii) – *no formal declaration necessary, as explained on Form B(i)*

Background information on outbreaks of reportable infectious diseases

(B) Animal disease

The Australian Government Department of Agriculture, Fisheries and Forestry is responsible for national coordination on animal health matters and for providing reports on Australia's animal health status, including a joint annual return to the World Organisation for Animal Health (OIE), the Food and Agriculture Organization (FAO) and the WHO.

The following sections contain information on significant animal disease events/issues in 2007. Australia publishes quarterly reports[4] and annual reports[5] on animal health incidents and status, as well as providing emergency, monthly, quarterly and annual reports to the World Organisation for Animal Health (OIE)[6]. Australia's status for OIE-listed diseases for 2007 is shown in the table that follows.

4 http://www.animalhealthaustralia.com.au/status/ahia.cfm

5 http://www.animalhealthaustralia.com.au/status/ahsq.cfm

6 http://www.oie.int/eng/info/en_infoan.htm

Status for OIE-listed diseases in 2007

Disease	Status	Date of last occurrence and notes
Multiple-species diseases		
Anthrax	Present	Limited distribution
Aujeszky's disease	Free	Never occurred
Bluetongue	Viruses present	Restricted to specific northern areas of the country; sentinel herd program
Brucellosis (*Brucella abortus*)	Free	Australia declared freedom in 1989
Brucellosis (*B. melitensis*)	Free	
Brucellosis (*B. suis*)	Serological evidence	Occurs only in feral pigs in northern Australia
Crimean Congo haemorrhagic fever	Free	Never occurred
Echinococcosis/hydatidosis	Present	
Foot-and-mouth disease	Free	1872; officially recognised by OIE as free without vaccination
Heartwater	Free	Never occurred
Japanese encephalitis	Serological evidence	Detected annually in Torres Strait, and on Cape York in 1998 and 2004
Leptospirosis	Present	
New World screw-worm fly (*Cochliomyia hominivorax*)	Free	Never occurred
Old World screw-worm fly (*Chrysomya bezziana*)	Free	Never occurred
Paratuberculosis	Present	National control/management programs
Q fever	Present	
Rabies	Free	1867
Rift Valley fever	Free	Never occurred
Rinderpest	Free	1923; officially recognised by OIE as free
Trichinellosis	Not reported	*Trichinella spiralis* not present; *T. pseudospiralis* present in wildlife
Tularaemia	Free	Never occurred
Vesicular stomatitis	Free	Never occurred
West Nile fever	Free	Never occurred
Cattle diseases		
Bovine anaplasmosis	Present	
Bovine babesiosis	Present	
Bovine genital campylobacteriosis	Present	
Bovine spongiform encephalopathy	Free	Never occurred; National Transmissible Spongiform Encephalopathy Freedom Assurance Program includes surveillance; official OIE 'negligible risk' status
Bovine tuberculosis	Free	Australia declared freedom in 1997; because of the nature of the disease, sporadic residual cases may occur (the last case was in 2002)
Bovine viral diarrhoea	Present	Bovine viral diarrhoea virus (BVDV) 1 — present; BVDV 2 — never occurred

Contagious bovine pleuropneumonia	Free	1967; Australia declared freedom in 1973; officially recognised by OIE as free
Enzootic bovine leucosis	Present	Voluntary accreditation and testing programs in place; very low prevalence
Haemorrhagic septicaemia	Free	Never occurred; strains of *Pasteurella multocida* present, but not the 6b or 6e strains that cause haemorrhagic septicaemia
Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis	Present	Bovine herpesvirus (BHV) 1.2b — present; BHV 1.1 and 1.2a — never occurred
Lumpy skin disease	Free	Never occurred
Malignant catarrhal fever (wildebeest only)	Free	
Theileriosis	Free	Nonpathogenic *Theileria buffeli* only present; *T. parva* and *T. annulata* not present
Trichomonosis	Present	
Trypanosomosis (tsetse borne)	Free	Never occurred
Sheep and goat diseases		
Caprine arthritis/encephalitis	Present	
Contagious agalactia	Not reported	*Mycoplasma agalactiae* has been isolated, but Australian strains do not produce agalactia in sheep
Contagious caprine pleuropneumonia	Free	Never occurred
Enzootic abortion of ewes (ovine chlamydiosis)	Not reported	Never occurred
Maedi–visna	Free	Never occurred
Nairobi sheep disease	Free	Never occurred
Ovine epididymitis (*Brucella ovis*)	Present	Voluntary accreditation schemes in all states
Peste des petits ruminants	Free	Never occurred
Salmonellosis (Salmonella Abortusovis)	Free	Never occurred; *S.* Abortusovis was isolated in 1994 from two children, but surveillance has shown no evidence of infection in sheep
Scrapie	Free	1952
Sheep-and-goat pox	Free	Never occurred
Equine diseases		
African horse sickness	Free	Never occurred
Contagious equine metritis	Free	1980
Dourine	Free	Never occurred
Equine encephalomyelitis (Eastern)	Free	Never occurred
Equine encephalomyelitis (Western)	Free	Never occurred
Equine infectious anaemia	Present	Limited distribution/sporadic occurrence
Equine influenza	Present	Outbreak occurred in last quarter of 2007; the last reported case occurred on 25 December 2007.
Equine piroplasmosis	Free	Last reported in 1976
Equine rhinopneumonitis	Present	
Equine viral arteritis	Serological evidence	

Glanders	Free	1891
Surra (*Trypanosoma evansi*)	Free	Never occurred
Venezuelan equine encephalomyelitis	Free	Never occurred
Swine diseases		
African swine fever	Free	Never occurred
Classical swine fever	Free	1962
Nipah virus encephalitis	Free	Never occurred
Porcine cysticercosis	Free	Never occurred
Porcine reproductive and respiratory syndrome	Free	Never occurred
Swine vesicular disease	Free	Never occurred
Transmissible gastroenteritis	Free	Never occurred
Avian diseases		
Avian chlamydiosis	Present	
Avian infectious bronchitis	Present	
Avian infectious laryngotracheitis	Present	
Avian mycoplasmosis (*Mycoplasma gallisepticum*)	Present	
Avian mycoplasmosis (*M. synoviae*)	Present	
Duck virus hepatitis	Free	Never occurred
Fowl cholera	Present	
Fowl typhoid	Free	Last reported in 1952
Highly pathogenic avian influenza	Free	1997
Infectious bursal disease (Gumboro disease)	Present	Infectious bursal disease occurs in a mild form; Gumboro disease does not occur
Low pathogenic notifiable avian influenza (poultry)	Free	Not present
Marek's disease	Present	
Newcastle disease	Viruses present	Last reported 2002
Pullorum disease	Present	Not in commercial chickens
Turkey rhinotracheitis	Free	Never occurred
Lagomorph diseases		
Myxomatosis	Present	Used as a biological control agent for wild rabbits
Rabbit haemorrhagic disease	Present	Used as a biological control agent for wild rabbits
Bee diseases		
Acariosis of bees	Free	Never occurred
American foulbrood	Present	
European foulbrood	Present	
Small hive beetle	Present	Restricted distribution
Tropilaelaps mite	Free	Never occurred
Varroosis	Free	*Varroa destructor* has never been reported in Australia

Other diseases		
Camel pox	Free	Never occurred
Leishmaniosis	Novel organism found	A new *Leishmania* species has been isolated from skin lesions in a group of captive red kangaroos. Occasionally, cases of leishmaniosis are reported in imported dogs.

Australia's status for other diseases of interest in 2007

Disease	Status	Date of last occurrence and notes
Actinomycosis	Present	
Avian encephalomyelitis	Present	
Avian leucosis	Present	
Avian salmonellosis (excluding fowl typhoid and pullorum disease)	Present	
Avian spirochaetosis	Present	
Blackleg	Present	
Botulism	Present	
Caseous lymphadenitis	Present	
Coccidiosis	Present	
Contagious ophthalmia	Present	
Contagious pustular dermatitis	Present	
Distomatosis (liver fluke)	Present	Restricted distribution
Enterotoxaemia	Present	
Equine coital exanthema	Present	
Filariosis	Present	
Footrot	Present	Restricted distribution
Infectious coryza	Present	
Intestinal salmonella infections	Present	
Listeriosis	Present	
Melioidosis	Present	Restricted distribution
Salmonellosis (*S.* Abortusequi)	Free	Never reported
Sheep mange	Free	1896
Strangles	Present	
Swine erysipelas	Present	
Toxoplasmosis	Present	
Ulcerative lymphangitis	Free	Never reported
Vibrionic dysentery	Present	
Warble fly infestation	Free	Never reported
Other clostridial infections	Present	
Other pasteurelloses	Present	

Comments on selected OIE-listed diseases

Bluetongue

Bluetongue viruses capable of causing disease are only found in parts of the far north of the Northern Territory and Western Australia. Relatively nonpathogenic strains (types 1 and 21) are found on the east coast in Queensland and northern New South Wales. There is little overlap between the distribution of vectors of bluetongue virus and major sheep populations, because the climate conditions that favour sheep production are not conducive to the vectors.

Transmission of bluetongue virus was seen in the endemic areas of far northern Australia and coastal New South Wales; in Western Australia bluetongue virus it was detected in the central and north Kimberley, but has almost disappeared from the Pilbara region. In the Northern Territory, bluetongue virus activity was late, with a number of seroconversions detected in May and June. Activity in New South Wales appeared to start on the far north coast and extended inland to Yarrowitch (as in the previous year), but did not reach further south than Kempsey (in contrast to the previous year, when it reached Camden). In Queensland, activity was largely confined to northern herds. Incidence was lower than average in the Northern Territory, low to moderate in Queensland and low to high in coastal New South Wales. Serotyping in the Northern Territory was difficult because there appeared to be a new strain (possibly BTV1) circulating; isolates will be characterised by the Australian Animal Health Laboratory. There was no evidence of bluetongue viruses in proximity to any of the major sheep populations in any state. Nationally, the areas free from bluetongue virus are marginally smaller this year. All regions in southern Australia and most pastoral regions in eastern Australia remain free from the virus.

Anthrax

Anthrax is a notifiable animal disease subject to compulsory government controls including quarantine, disposal of carcasses, and vaccination. It is present in well-defined areas in the northern and northeastern districts of Victoria and central New South Wales. In these areas, anthrax has a low prevalence, and occurs only sporadically. Occasional outbreaks have occurred in other States. South Australia last recorded an outbreak in 1914, and Tasmania in 1933. Anthrax was diagnosed in Queensland in 1993 and 2002, and in Western Australia in 1995. The disease has never been reported in the Northern Territory. During 2007, there were seven confirmed incidents of anthrax in New South Wales, and one in Victoria.

Equine influenza

In August, equine influenza (EI) was diagnosed in an equestrian centre in central Sydney. Australia aimed to control and eradicate EI as quickly as possible. During the outbreak, a number of technical working groups, each with a specific focus, were established to ensure that the best possible technical advice was available and to mount an effective and rapid response. The initial horse standstill and subsequent movement restrictions, combined with strong messages on biosecurity, were effective in containing the disease to areas in New South Wales and Queensland. As the outbreak progressed, horse movements were carefully managed and only permitted where risk assessments determined that the chance of carrying EI to another area was very low. By the end of 2007, equestrian and racing events had recommenced where biosecurity could be effectively implemented and the risk had been assessed as low. Vaccine was used

during the outbreak to create buffer zones of vaccinated horses around areas of high disease incidence. Where appropriate, vaccination was also used to assist businesses that were at risk as a result of the outbreak. Australia so far remains on track to eradicate EI by mid-2008.

Attachment 3.3

Information relevant to Measure B(ii) – *no formal declaration necessary, as explained on Form B(i)*

Background information on outbreaks of reportable infectious diseases

(C) Plant diseases

The Australian Government Department of Agriculture, Fisheries and Forestry, through the Office of the Chief Plant Protection Officer, is the peak organisation that gathers information on pests of plants. The Department is notified of exotic incursions through State Government agricultural, forestry and natural resource agencies. It also provides national leadership in responding to incursions of exotic pests and diseases of plants.

New plant pests and diseases recorded in Australia for 2007

Pest	Where Detected	State	Date of detection
Sycamore Lace Bug	Plane Trees	NSW	19/03/2007
(Corythuca cilliata)	Carrots	NSW	26/03/2007
Powdery Mildew	Personal effects consignment	WA	20/04/2007
(Erysiphe heraclei)	Plane Trees	NSW	8/05/2007
Khapra Beetle	Cutting propagations	QLD	23/05/2007
(Trogoderma granarium)	Cherry tomato	WA	8/06/2007
Canker Stain	Commercial cultivated mushroom (agaricus bisporus)	VIC	4/09/2007
(Ceratocystis platani)	Brugmansia sp. in a nursery	NSW	13/09/2007
Chrysanthemum Chloritic	On catmint within a greenhouse	SA	26/09/2007
Mottle Viroid	On surfaces of rotting scales	TAS	15/10/2007
Potato Spindle Tuber Viroid	On leaves of tomato plants	WA	5/11/2007
Hormiactis Cap Spotting	On two mango trees at a reseach station	NT	13/11/2007

CONFIDENCE BUILDING MEASURE B(ii) *[Form B(ii)]*

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

As noted on Form B(i), Australia had no outbreaks of infectious diseases and similar occurrences caused by toxins that deviate from the normal pattern. However, Attachments 3.1 and 3.2 of Form B(i) provide information relevant to that requested below.

1. Time of cognizance of the outbreak .....

2. Location and approximate area affected .....

3. Type of disease/intoxication .....

4. Suspected source of disease/ intoxication .....

5. Possible causative agent(s) .....

6. Main characteristics of systems .....

7. Detailed symptoms, when applicable

- respiratory .....
- circulatory .....
- neurological/behavioural .....
- intestinal .....
- dermatological .....
- nephrological .....
- other .....

8. Deviation(s) from the normal pattern as regards

- type .....
- development .....
- place of occurrence .....
- time of occurrence .....
- symptoms .....
- virulence pattern .....

- drug resistance pattern .....
- agent(s) difficult to diagnose .....
- presence of unusual vectors .....
- other .....

9. Approximate number of primary cases .....

10. Approximate number of total cases .....

11. Number of deaths .....

12. Development of the outbreak .....

13. Measures taken .....

CONFIDENCE BUILDING MEASURE C *[Form C]*

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

> "Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research."

Australia's submission of Confidence Building Measure C is at **Attachments 4.1 and 4.2**. Information relating to "Modality 2", below, is provided with respect to (A) The Australian Animal Health Laboratory (see Attachment 4.1), and (B) Defence Science and Technology Organisation (see Attachment 4.2).

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.

2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, inter alia, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.

3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Encouragement of publication of results and promotion of use of knowledge

(A) The Australian Animal Health Laboratory (AAHL)

AAHL's policy is to encourage the publication of research results. The following were published by staff at AAHL during 2007.

Journal Articles

Abraham G, McCabe P. 2007. Reliability of ULPA filters in air handling systems. Applied Biosafety. 12: 184-186.

Andrew ME, Morris KR, Bruce MP, O'Neil TE, Jansen E , Coupar BEH, Strom ADG. 2007. Sustained biological effects of porcine Interleukin 5 delivered to pigs as recombinant protein or via a DNA vector. Cytokine. 40: 193-200.

Asif M, Lowenthal JW, Ford ME, Schat KA, Kimpton WG, Bean AGD. 2007. Interleukin-6 expression after infectious bronchitis virus infection in chickens. Viral Immunology. 20: 479-86.

Babiuk SL, Parkyn GR, Copps JS, Laurence JE, Sabara MI, Bowden TR, Boyle DB, Kitching RP. 2007. Evaluation of an ovine testis cell line (OA3.Ts) for propagation of Capripoxvirus isolates and development of an immunostaining technique for viral plaque visualization. Journal of Veterinary Diagnostic Investigation. 19: 486-491.

Bannister SC, Wise TG, Cahill DM, Doran TJ. 2007. Comparison of chicken 7SK and U6 RNA polymerase III promoters for short hairpin RNA expression. BMC Biotechnol. 7: 79.

Bishop KA, Stantchev TS, Hickey AC, Khetawat D, Bossart KN, Krasnoperov V, Gill P, Feng YR, Wang LF, Eaton BT, Wang LF, Broder CC. 2007. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. Journal of Virology. 81: 5893-5901.

Bossart KN, Bingham J, Middleton DJ. 2007. Targeted strategies for Henipavirus therapeutics. Open Virology Journal. 1: 14-25.

Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, Eaton BT, Wang LF. 2007. Neutralization assays for differential Henipavirus serology using Bio-Plex protein array systems. Journal of Virological Methods. 142: 29-40.

Bublot M, Pritchard M, Cruz JS, Mickle TR, Selleck PW, Swayne DE. 2007 . Efficacy of a Fowlpox-vectored Avian Influenza H5 Vaccine against Asian H5N1 Highly Pathogenic Avian Influenza Virus Challenge. Avian Diseases. 51: 498-500.

Chen JM, Yaiw KC, Yu M, Wang LF, Wang QH, Crameri GS, Wang ZL. 2007. Expression of truncated phosphoproteins of Nipah virus and Hendra virus in Escherichia coli for the

differentiation of Henipavirus infections. Biotechnology Letters. 29: 871-875.

Chua KB, Crameri GS, Hyatt AD, Yu M, Tompang MR, Rosli J, McEachern JA, Crameri SG, Kumarasamy V, Eaton BT, Wang LF. 2007. A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proceedings of the National Academy of the Sciences. 104: 11424-11429.

Chua KB, Wong EMH, Cropp BC, Hyatt AD. 2007. Role of electron microscopy in Nipah virus outbreak investigation and control. Medical Journal of Malaysia. 62: 139.

Chua TH, Ellis TM, Wong CW, Guan Y, Ge SX, Peng G, Lamichhane C, Maliadis C, Tan SW, Selleck PW, Parkinson J. 2007. Performance evaluation of five detection tests for avian influenza antigen with various avian samples. Avian Diseases. 51: 96-105.

Corney B, Diallo IS, Wright L, Hewitson GR, Kelly M, Burrell P, Duffy P, Stephens C, Rodwell B, Boyle DB, Blackall PJ. 2007. Pasteurella multocida detection by 5' Taq nuclease assay: a new tool for use in diagnosing fowl cholera. Journal of Microbial Methods. 69: 376-380.

Cowled CJ, Melville L, Weir R, Walsh S, Hyatt AD, Van driel R, Davis S, Gubala A, Boyle DB. 2007. Genetic and epidemiological characterization of Middle Point orbivirus, a novel virus isolated from sentinel cattle in northern Australia. Journal of General Virology. 88: 3413-3422.

Crane MStJ, McColl KA, Davies KR, Williams LM, Young JG, Moody NJ. 2007. Evaluation of the draft Australian and New Zealand Standard Diagnostic Procedure (ANZSDP) for PCR-detection of Betanodaviruses. Fish Pathology. 42: 173-179.

Cui J, Han N, Streiker D, Li G, Tang X, Shi Z, Hu Z, Zhao G, Fontanet A, Guan Y, Wang LF, Jones G, Field HE, Daszak P, Zhang S. 2007. Evolutionary relationships between bat coronaviruses and their hosts. Emerging Infectious Diseases. 13: 1526-1532.

Cunningham AA, Hyatt AD, Russell P, Bennett OM. 2007. Experimental transmission of a ranavirus disease of common toads (Bufo bufo) to common frogs (Rana temporaria). Epidemiology and Infection. 135: 1213-1216.

Cunningham AA, Hyatt AD, Russell P, Bennett PM. 2007. Emerging epidemic diseases of frogs in Britain are dependent on the source of ranavirus agent and the route of exposure. Epidemiology and Infection. 135: 1200-1212.

Daniels PW, Halpin K, Hyatt AD, Middleton DJ. 2007. Infection and disease in reservoir and spillover hosts: determinants of pathogen emergence. Current Topics in Microbiology and Immunology. 315: 113-31.

De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Venturi V, Davenport MP, Kent SJ. 2007. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. Journal of Virology. 81: 292-300.

Dimitrov DS, Wang LF. 2007. In utero transmission of Nipah virus: role played by pregnancy

and vertical transmission in Henipavirus epidemiology. Journal of Infectious Diseases. 196: 807-809.

Edgar JA, Boppre M, Kaufmann E. 2007. Insect-synthesised retronecine Ester alkaloids: precursors of the common arctiine (lepidoptera) Pheromone Hydroxydanaidal. Journal of Chemical Ecology. 33: 2266-2280.

Fan B, Chen SL, Kijas JH, Liu B, Yu M, Zhao SH, Zhu MJ, Xiong TA, Li K. 2007. Phylogenetic relationships among chinese indigenous goat breeds inferred from mitochondrial control region sequence. Small Ruminant Research. 73: 262-266.

Ferguson DM, Warner RD, Walker PJ, Knee B. 2007. The effect of cattle marketing method on beef quality and palatability. Australian Journal of Experimental Agriculture. 47: 774-781.

Foord AJ, Muller JD, Yu M, Wang. LF, Heine HG. 2007. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC. Journal of Immunological Methods. 321: 142-151.

Garcia G, Cunningham AA, Horton DL, Garner TWJ, Hyatt AD, Hengstberger S, Lopez J, Ogrodowczyk A, Fenton C, Fa JE. 2007. Mountain chickens Leptodactylus fallax and sympatric amphibians appear to ne disease free on Montserrat. Oryx. 41: 398-401.

George N, Henry DA, Yan G, Byrne M. 2007. Variability in feed quality between populations of Acacia saligna (Labill.) H. Wendl. (Mimosoideae) - implications for domestication. Animal Feed Science and Technology. 136: 109-127.

Gerhold RW, Tate CM, Gibbs SEJ, Mead DG, Allison AB, Fischer JR. 2007. Necropsy findings and arbovirus surveillance in mourning doves from the southeastern United States. Journal of Wildlife Diseases. 43: 129-35.

Gleason FH, Mozley-Standridge SE, Porter D, Boyle DG, Hyatt AD. 2007. Preservation of Chytridiomycota in culture collections. Mycological Research. 111: 129-36.

Hagmaier K, Stock N, Precious B, Childs K, Wang LF, Goodbourn S, Randall RE. 2007. Mapuera virus, a rubulavirus that inhibits interferon signalling in a wide variety of mammalian cells without degrading STATs. Journal of General Virology. 88: 956-66.

Halpin K, Hyatt AD, Plowright RK, Epstein JH, Daszak P, Field HE, Wang LF, Daniels PW. 2007. Emerging viruses: coming in on a wrinkled wing and a prayer. Clinical Infectious Diseases. 44: 711-7.

Halpin K, Mungall BA. 2007. Recent progress in Henipavirus research. Comparative Immunology, Microbiology and Infectious Diseases. 30: 287-307.

Hampson K, Dushoff J, Bingham J, Bruckner G, Ali YH, Dobson A. 2007. Synchronous cycles of domestic dog rabies in sub-Saharan Africa and the impact of control efforts. Proceedings of the National Academy of Sciences of the United States of America. 104: 7717-7722.

Heine HG, Trinidad L, Selleck PW, Lowther SL. 2007. Rapid detection of highly pathogenic avian influenza H5N1 by TaqMan RT-PCR. Avian Diseases. 51: 370-372.

Henry DA. 2007. Developing disease outbreak control model. Faming Ahead. 180: 32.

Hurt AC, Selleck PW, Komadina N, Shaw R, Brown L, Barr IG. 2007. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research. 73: 228-231.

Hutchinson S, Evans D, Corino G, Kattenbelt J. 2007. An evaluation of the action of thioesterases on the surface of wool. Enzyme and Microbial Technology. 40: 1794-1800.

Hyatt AD, Boyle DG, Olsen V, Boyle DB, Berger L, Obendorf D, Dalton A, Kriger K, Hero M, Hines H, Phillott R, Campbell R, Marantelli G, Gleason F, Colling A. 2007. Diagnostic Assays and sampling protocols for the detection of Batrachochytrium dendrobatidis. Diseases of Aquatic Organisms. 73: 175-192.

Ingham AB, Moore RJ. 2007. Recombinant production of antimicrobial peptides in heterologous microbial systems. Biotechnology and Applied Biochemistry. 47: 1-9.

Janardhana V, Ford ME, Bruce MP, Broadway MM, O'Neil TE, Karpala AJ, Asif M, Browning GF, Tivendale KA, Noormohammadi AH, Lowenthal JW, Bean AGD. 2007. IFN-gamma enhances immune responses to E. coli Infection in the chicken. Journal of Interferon and Cytokine Research. 27: 937-946.

Jeggo MH. 2007. The changing world of biocontainment and biosecurity. Developments in Biologicals. 128: 47-51.

Jenkins KA, Bean AGD, Lowenthal JW. 2007. Avian genomics and the innate immune response to viruses. Cytogenetic and Genome Research. 117: 207-212.

Juozapaitis M, Serva A, Kucinskaite I, Zvirbliene A, Slibinskas R, Staniulis J, Sasnauskas K, Shiell BJ, Bowden TR, Michalski WP. 2007. Generation of Menangle virus nucleocapsid-like particles in yeast Saccharomyces cerevisiae. Journal of Biotechnology. 130: 441-447.

Juozapaitis M, Serva A, Zvirbliene A, Slibinskas R, Staniulis J, Sasnauskas K, Shiell BJ, Wang LF, Michalski WP. 2007. Generation of Henipavirus nucleocapsid proteins in yeast Saccharomyces cerevisiae. Virus Research. 124: 95-102.

Karlen GAM, Hemsworth., Gonyou HW, Fabrega E, Strom ADG, Smits RJ. 2007. The welfare of gestating sows in conventional stalls and large groups on deep litter. Applied Animal Behaviour Science. 105: 87-101.

Khounsy S, Gleeson LJ, Van Aken D, Westbury HA, Blacksell SD. 2007. Diagnosis of classical swine fever in a limited resource setting: The influence of pig breed on methodology and sample selection. Tropical Animal Health and Production. 39: 21-25.

Kitching P, Hammond JM, Jeggo MH, Charleston B, Paton D, Rodrigues L, Heckert R. 2007.

Global FMD control - Is it an option. Vaccine. 25: 5660-5664.

Kite V, Boyle DB, Heine HG, Pritchard LI, Garner M, East I. 2007. A serological and virological survey for evidence of infection with Newcastle disease virus in Australian chicken farms. Australian Veterinary Journal. 85: 236-42.

Kowalski MC, Cahill D, Doran TJ, Colegate SM. 2007. Development and application of polymerase chain reaction-based assays for Rathayibacter toxicus and a bacteriophage associated with annual ryegrass (Lolium rigidum) toxicity. Australian Journal of Experimental Agriculture. 47: 177-183.

Lambeth LS, Moore RJ, Muralitharan MS, Doran TJ. 2007. Suppression of bovine viral diarrhoea replication by small interfering RNA and short hairpin RNA-mediated RNA interference. Veterinary Microbiology. 119: 132-143.

Layton DS, Strom ADG, O'Neil TE, Broadway MM, Stephenson GL, Morris KR, Muralitharan MS, Sandrin MS, Ierino FL, Bean AGD. 2007. Development of an anti-porcine CD34 monoclonal antibody that identifies hematopoietic stem cells. Experimental Haematology. 35: 171-178.

Magoffin DE, Halpin K, Rota PA, Wang LF. 2007. Effects of single amino acid substitutions at the E residue in the conserved GDNE motif of the Nipah virus polymerase L protein. Archives of Virology. 152: 827-832.

Magoffin DE, Mackenzie JS, Wang LF. 2007. Genetic analysis of J-virus and Beilong virus using minireplicons. Virology. 364: 103-111.

McColl KA, Chamberlain T, Lunt RA, Newberry KM, Westbury HA. 2007. Susceptibility of domestic dogs and cats to Australian bat lyssavirus (ABLV). Veterinary Microbiology. 123: 15-25.

McColl KA, Sunarto A, Williams LM, Crane MStJ. 2007. Koi Herpesvirus: dreaded pathogen or white knight? Aquaculture Health International. 9: 4-6.

McKean SC, Davies JK, Moore RJ. 2007. Expression of Phospholipase D, the major virulence factor of Corynebacterium pseudotuberculosis, is regulated by environmental factors and plays a role in macrophage death. Microbiology. 153: 2203-2211.

McKean SC, Davies JK, Moore RJ. 2007. Probing the heat shock response of Corynebacterium pseudotuberculosis: the major virulence factor, phospholipase D, is down-regulated at 43^{0}c. Research in Microbiology. 158: 279-286.

McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. 2007. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases. 13: 1354-1357.

McNeilly CL, Beagley KW, Moore RJ, Haring V, Timms P, Hafner LM. 2007. Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine. 25: 2643-55.

Middleton DJ, Bingham J, Selleck PW, Lowther SL, Gleeson LJ, Lehrbach P, Robinson S, Rodenberg J, Kumar M, Andrew ME. 2007. Efficacy of inactivated vaccines against H5N1 avian influenza in ducks. Virology. 359: 66-71.

Middleton DJ, Morrissy CJ, van der Heide BM, Russell GM, Braun MA, Westbury HA, Halpin K, Daniels PW. 2007. Experimental Nipah virus infection in pteropid bats (Pteropus poliocephalus). Journal of Comparative Pathology. 136: 266-272.

Mohan CV, Walker PJ. 2007. Inter-calibration of White Spot Syndrome Virus PCR Laboratories in India. Aquaculture Health International. 8: 16.

Mungall BA, Middleton DJ, Crameri GS, Halpin K, Bingham J, Eaton BT, Broder CC. 2007. Vertical transmission and fetal replication on Nipah virus in an experimentally infected cat. Journal of Infectious Diseases. 196: 812-816.

Pallister JA, Goldie S, Coupar BEH, Shiell BJ, Michalski WP, Siddon N, Hyatt AD. 2007. Bohle iridovirus as a vector for heterologous gene expression. Journal of Virological Methods. 146: 419-423.

Pallister JA, Gould A, Harrison D, Hyatt AD, Jancovich J, Heine HG. 2007. Development of real-time PCR assays for the detection and differentiation of Australian and European ranaviruses. Journal of Fish Diseases. 30: 427-438.

Pan Y, Shiell BJ, Wan J, Coventry MJ, Michalski WP, Lee A, Roginski H. 2007. The molecular characterisation and antimicrobial properties of amidated bovine beta-lactoglobulin. International Dairy Journal. 17: 1450-1459.

Pan Y, Shiell BJ, Wan J, Coventry MJ, Roginski H, Lee A, Michalski WP. 2007. The molecular characterisation and antimicrobial activity of amidated bovine lactoferrin. International Dairy Journal. 17: 606-616.

Pan Y, Wan J, Roginski H, Lee A, Shiell BJ, Michalski WP, Coventry MJ. 2007. Comparison of the effects of acylation and amidation on the antimicrobial and antiviral properties of lactoferrin. Letters in Applied Microbiology. 44: 229-234.

Pant G, Selleck PW. 2007. Surveillance for Avian Influenza in Nepal 2004-2005. Avian Diseases. 51: 352-354.

Patch JR, Crameri GS, Wang LF, Eaton BT, Broder CC. 2007. Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virology Journal. 4: 1-36.

Pearl CA, Bull EL, Bowerman J, Adams MJ, Hyatt AD, Wente WH. 2007. Occurrence of the amphibian pathogen Batrachochytrium dendrobatidis in the pacific northwest. Journal of Herpetology. 41: 145-149.

Porotto M, Carta P, Deng Y, Kellogg GE, Whitt M , Lu M, Mungall BA, Moscona A. 2007. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. Journal of

Virology. 81: 10567-10574.

Pyecroft SB, Pearse AM, Loh R, Swift K, Belov K, Fox N, Noonan E, Hayes D, Hyatt AD, Wang LF, Boyle DB, Church J, Middleton DJ, Moore RJ. 2007. Towards a case definition for Devil Facial Tumour Disease: What is it? Ecohealth. 4: 346-351.

Quan PL, Palacios G, Jabado OJ, Conlan S, Hirschberg DL, Pozo F, Jack PJ, Cisterna D , Renwick N, Hui J, Drysdale A, Amos-Ritchie R, Baumeister E, Savy V, Lager KM, Richt JA, Boyle DB, Garcia-Sastre A, Casas I, Perez-Brena P, Briese T, Lipkin WI. 2007. Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. Journal of Clinical Microbiology. 45: 2359-2364.

Robinson K, Bell LW, Bennett RG, Henry DA, Tibbett M, Ryan MH. 2007. Perennial legumes native to Australia - a preliminary investigation of nutritive value and response to cutting. Australian Journal of Experimental Agriculture. 47: 170-176.

Seimon TA, Seimon A, Daszak P, Halloy S, Schlogel LM, Aguilar CA, Sowell P, Hyatt AD, Konecky B, Simmons J. 2007. Upward range extension of Andean anurans and chytridiomycosis to extreme elevations in response to tropical deglaciation. Global Change Biology. 13: 288-299.

Shiell BJ, Tachedjian M, Bruce K, Beddome G, Farn JL, Hoyne PA, Michalski WP. 2007. Expression, purification and characterization of phospholipase B from Moraxella bovis with anomalous electrophoretic behavior. Protein Expression and Purification. 55: 262-272.

Stewart DJ, Vaughan JA, Stiles PL, Noske PJ, Tizard MLV, Prowse SJ, Michalski WP, Butler KL, Jones SL. 2007. A long-term bacteriological and immunological study in Holstein-Friesian cattle experimentally infected with Mycobacterium avium subsp. paratuberculosis and necropsy culture results for Holstein-Friesian cattle, Merino sheep and Angora goats. Veterinary Microbiology. 122: 83-96.

Tizard MLV, Moore RJ, Lambeth LS, Lowenthal JW, Doran TJ. 2007. Manipulation of small RNAs to modify the chicken transcriptome and direct productivity traits. Cytogenetic and Genome Research. 117: 158-164.

Wang LF, Eaton BT. 2007. Bats, civets and the emergence of SARS. Current Topics in Microbiology and Immunology. 315: 325-44.

Wang LF, Hansson E, Yu M, Chua KB, Mathe NA, Crameri GS, Rima BK, Moreno-Lopez J, Eaton BT. 2007. Full-length genome sequence and genetic relationship of two paramyxoviruses isolated from bats and pigs in the Americas. Archives of Virology. 152: 1259-1271.

Wang YH, Reverter A, Kemp DH, McWilliam SM, Ingham AB, Davis CK, Moore RJ, Lehnert SA. 2007. Gene expression profiling of Hereford Shorthorn cattle following challenge with Boophilus microplus tick larvae. Australian Journal of Experimental Agriculture. 47: 1397-1407.

Wells JW, Cowled CJ, Darling D, Guinn BA, Farzaneh F, Noble A, Galea-Lauri J. 2007. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunology, Immunotherapy. 56: 1861-1873.

Wells JW, Cowled CJ, Giorgini A, Kemeny DM, Noble A. 2007. Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration. Journal of Allergy and Clinical Immunology. 119: 226-34.

Wilcox BR, Yabsley MJ, Ellis AE, Stallknecht DE, Gibbs SEJ. 2007. West Nile Virus antibody prevalence in American Crows (Corvus brachyrhynchos) and fish crows (Corvus ossifragus) in Georgia, USA. Avian Diseases. 51: 125-128.

Wise TG, Schafer DJ, Lambeth LS, Tyack SG, Bruce MP, Moore RJ, Doran TJ. 2007. Characterization and comparison of chicken U6 promoters for the expression of short hairpin RNAs. Animal Biotechnology. 18: 153-162.

Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, Zheng L, Lan T, Wang LF, Liang GD. 2007. Duration of antibody responses after severe acute respiratory syndrome. Emerging Infectious Diseases. 13: 1562-1564.

Yaiw KC, Bingham J, Crameri GS, Mungall BA, Hyatt AD, Eaton BT, Shamala D, Wang LF, Wong KT. 2007. Experimental Tioman virus infection in pigs. Malaysian Journal of Pathology. 29: 202.

Yaiw KC, Crameri GS, Wang LF, Chong HT, Chua KB, Tan CT, Goh KJ, Shamala D, Wong KT. 2007. Serological evidence of possible human infection with Tioman virus, a newly described paramyxovirus of bat origin. Journal of Infectious Diseases. 196: 884-886.

Yaiw KC, Ong KC, Chua KB, Bingham. J., Wang LF, Shamala D, Wong KT. 2007. Tioman virus infection in experimentally infected mouse brain and its association with apoptosis. Journal of Virological Methods. 143: 140-146.

Zhu Z, Chakroborti S, He Y, Roberts A, Sheahan T, Xiao A, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric L, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proceedings of the National Academy of the Sciences of the United States of America. 104: 12123-12128.

Book Chapters

Bossart KN, Broder CC. 2007. Paramyxovirus entry. Pohlmann, S, Simmons, G. (eds). Viral entry into host cells Landes Bioscience, Austin, Texas, USA.

Boyle DB. 2007. Genus Avipoxvirus. Mercer, AA, Schmidt, A, Weber, O. (eds). Poxviruses. Mercer AA, Schmidt A, Weber O. (eds). Birkhauser Advances in Infectious Diseases. Birkhauser Verlag, Basel, Switzerland. Pp. 217-251.

Daniels PW, Halpin K, Hyatt AD, Middleton DJ . 2007. Infection and disease in reservoir and spillover hosts: determinants of pathogen emergence. Childs, JE, Mackenzie, JS, Richt, JA. (eds). Wildlife and emerging zoonotic diseases: the biology, circumstances and consequences of

cross-species transmission Current Topics in Microbiology and Immunology. Springer, Berlin. Pp. 113-132.

Doran TJ, Lambeth LS. 2007. Transforming livestock with transgenics: is designed resistance to viral diseases the way forward? Swain, DL, Charmley, E, Steel, JW, Coffey, SG. Redesigning animal agriculture: the challenge of the 21st century CABI, Wallingford, UK.

Eaton BT, Mackenzie JS, Wang LF. 2007. Henipaviruses. Knipe, DM, Griffin, DE, Lamb, RA, Straus, SE, Howley, PM, Martin, MA, Roizman, B. (eds). Field's virology Lippincott,Williams & Wilkins, Philadelphia, USA. Pp. 1587-1600.

Wang LF, Eaton BT. 2007. Bats, civets and the emergence of SARS. Childs, JE, Mackenzie, JS, Richt, JA. (eds). Wildlife and emerging zoonotic diseases: the biology, circumstances and consequences of cross-species transmission Current Topics in Microbiology and Immunology. Springer, Berlin. Pp. 325-344.

Book Whole

Heine HG, Trinidad L. 2007. Implementation and Validation of Avian Influenza Virus TaqMan Assays on Various Platforms in Different State Veterinary Diagnostic Laboratories. CSIRO Livestock Industries, Geelong, Vic.

Conference Proceedings

Aljofan M, Mungall BA. 2007. Development of a high throughput antiviral screening assay for Nipah virus at BSL-4. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Group.

Alvarez AC, Brunck M, Virtue ER, Lai R, Gibbs A, Chen W, Bletchly C, Heine HG, Barnard RT. 2007. One-step reverse transcription PCR amplification of the neuraminidase gene from multiple subtypes of influenza a. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel, St Kilda, Vic. The Workshop.

Babiuk SL, Bowden TR, Parkyn GR, Dalman B, Boyle DB, Kitching P, Copps JS. 2007. Characterization of a live sheep pox virus vaccine . Keystone Symposia Conference "Challenges of Global Vaccine development T1" . Cape Town, South Africa. The Symposia.

Bannister SC, Tizard MLV, Smith CS, Doran TJ, Sinclair A. 2007. MicroRNA expression profiling of chick embryonic gonads during sex determination. ComBio 2007 Combined Conference Abstracts. Sydney Convention and Exhibition Center, Sydney. The Conference.

Bingham J. 2007. Immunohistochemical detection of infectious pathogens in wildlife. Wildlife Disease Association Australasian Section Annual Conference. Dryandra Woodlands, WA. The Conference.

Bossart KN, Wang LF. 2007. Novel multiplexed assays for Henipavirus serology. Henipavirus Research Adoption Forum. Rydges Lakeside, Canberra. The Forum.

Bossart KN. 2007. A comprehensive approach to Henipavirus surveillance based on ecology, immunology and molecular pathogenesis. Workshop on Converging Technologies for Biosecurity. Australian Academy of Technological Sciences and Engineering, Melbourne. The Workshop.

Bowden TR, Babiuk SL, Anderson MP, Parkyn GR, Kitching RP, Copps JS, Boyle DB. 2007. Capripoxvirus tropism and shedding: a quantitative time-course study in experimentally infected sheep and goats. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Bowden TR, Coupar BEH, Babiuk SL, White JR, Boyd V, Duch CJ, Anderson PJ, Stevens V, Parkyn GR, Kitching RP, Copps JS, Boyle DB. 2007. An indirect ELISA, based on recombinant Capripoxvirus antigens for detection of antibodies to sheeppox and goatpox viruses. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Bowden TR. 2007. Bringing diagnostic capabilities for diseases caused by capripoxviruses - Sheep pox, Goat pox and lumpy skin disease into the modern era. ASM 2007 Annual Scientific Meeting of the Australian Society for Microbiology. Adelaide Convention Centre, Adelaide. The Convention.

Boyle DB, Bowden TR, Boyd V, Duch CJ, Anderson MAP, Stevens V, White JR, Coupar BEH, Babiuk SL, Parkyn GR, Kitching RP, Copps JS. 2007. An indirect ELISA, based upon recombinant Capripoxvirus antigens, for serological detection of Sheeppox, goatpox and lumpy skin disease. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Boyle DB, Bulach D, Spiro D, Janies D. 2007. Understanding the genotypes of avian influenza viruses circulating in Australia. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Boyle DB, Jack PJM. 2007. Pathogen detection and characterisation by microarrays. Devil Facial Tumour Disease Senior Scientist's Scientific Forum. Life Sciences Lecture Theatre, Sandy Bay Campus, University of Tasmania. The Forum.

Boyle DB. 2007. Biosecurity from test development to border protection. BioGeelong Symposium. Deakin Management Centre, Geelong. The Symposium.

Boyle DB. 2007. On wings and the wind: Pathogen entry to and exit from Australia. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Buller NB, McLetchie HM, Fenwick S, Nicholls P, Gudkovs N, Jones JB, Alderman D. 2007. Diagnostic tests for the detection of A. invadans (epizootic ulcerative syndrome) and A. astaci

(crayfish plague). Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Calisher C, Wang LF. 2007. Diagnosis and control of emerging viral infections. 25th International Congress of Chemotherapy (ICC) and the 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany. The Congress.

Carson J, Higgins M, Wilson T, Gudkovs N, Bryant T. 2007. Phenotyping as a practical basis for the identification of Vibrionaveae: finding a purpose for bacterial taxonomy. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Castillo-Alvarez LA, Brunck M, Lai R, Virtue ER, Gibbs A, Chen W, Bletchly C, Heine HG, Barnard RT. 2007. One-step reverse-transcription PCR amplification of the neurominidase gene from multiple subtypes of Influenza A. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Castillo-Alvarez LA, Brunck M, Lai R, Virtue ER, Gibbs A, Chen W, Bletchly C, Heine HG, Barnard RT. 2007. One-step reverse-transcription PCR amplification of the Neurominidase gene segment from multiple subtypes of Influenza A. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Chua TH, Ellis TM, Wong CW, Guan Y, Ge SX, Peng G, Lamichhane C, Maliadis C, Tan SW, Selleck PW, Parkinson J. 2007. Performance evaluation of five detection tests for avian influenza antigen with various avian samples. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Colling A. 2007. Assay validation: from theory to practice. AAHL Seminar Series. Geelong, Vic. CSIRO Livestock Industries.

Conlan JV, Colling A, Morrissy CJ, Gleeson LJ, Wilks CR, Khounsy S. 2007. Application of immunomagnetic bead technology for improved diagnosis of Classical Swine Fever in a low technology setting. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Corbeil S, Liggins G, Upston J, Crane MStJ. 2007. Detection of perkinsus olensi in abalone tissues by TaqMan real-time PCR assay. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Cowled CJ, Melville L, Weir R, Walsh S, Boyle D.B. 2007. The discovery and characterisation of middle point orbivirus, a novel virus isolated from sentinel cattle in Northern Australia. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Cowled CJ, Melville L, Weir R, Walsh S, Boyle DB. 2007. The discovery and characterisation of Middle point orbivirus, a novel virus isolate from Sentinel cattle in Northern Australia. 4th

Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Crameri GS, Hyatt AD, Yu M, McEachern JA, Crameri SG, Wang LF. 2007. Melaka virus and other emerging bat orthoreoviruses. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Crameri GS, Yu M, Smith CS, McEachern J.A., Bingham J, De Jong C, Field HE, Eaton BT, Wang LF. 2007. The role of bats in the emergence of SARS Coronavirus. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Crane MStJ. 2007. Aquatic Animal Health Status in Australia. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Crane MStJ. 2007. FRDC Aquatic Animal Health Subprogram. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Crockford M, Jones B, Whittington R, Crane MStJ, Wilcox G, McColl KA. 2007. Pilchard Herpesvirus infection in wild pilchards. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Cummins DM, Tyack SG, Johnson MA, Doran TJ, Hammond JM. 2007. Porcine adenovirus as a delivery vector for short hairpin RNA (shRNA). RNAI Europe 2007. Barcelona, Spain. The Conference.

Cummins DM, Tyack SG, Johnson MA, Doran TJ, Hammond JM. 2007. Porcine adenovirus as a delivery vector for short hairpin RNA (shRNA). 4th Annual RNAI Europe. Barcelona, Spain. The Conference.

Daniels PW, Pritchard LI, Lunt RA. 2007. BTV in Australia: relationships with the Asia/Pacific Episystem. OIE Ad hoc working group on BT. Teramo, Italy. The Group.

Daniels PW, Staff at the Australian Animal Health Laboratory. 2007 . Diagnosis and characterization of Equine Influenza (EI) in Australia: A/Equine/Sydney/2888-8/2007 H3N8. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Daniels PW. 2007. Bluetongue in Europe. AVA Annual Conference. Melbourne Convention Centre, Melbourne. The Conference.

Daniels PW. 2007. Nipah and Hendra viruses and Pteropid bats: more outbreaks, new observations, future challenges. IMED 2007 International Meeting on Emerging Diseases and Surveillance. Vienna, Austria. The Meeting.

Di Rubbo A, Halpin K, Meers J, Michalski WP. 2007. Developing tools for serological studies

on Pteropid bats (Flying foxes). Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Di Rubbo A. 2007. Developing tools for serological studies on Pteropid bats (Flying Foxes). Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Dissertation

Durr PA, Zupanovic I, Watson J, Wright L, Johnson MA. 2007. Beyond the laboratory gate: enhancing a laboratory information management system (LIMS) for exotic animal disease preparedness. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Eaton BT. 2007. Advances in diagnostics: implications for the Epidemiologist. Australian College of veterinary scientists Epidemiology Chapter Meeting. Morton Room, Gold Coast International Hotel, Surfers Paradise, QLD. The Meeting.

Foord AJ, Heine HG. 2007. Adaption of real time pcr assays for detection of new and evolving avian influenza virus strains. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Gibbs SEJ, Widowati N, Axell A, Lunt RA, Groocock C , Lauerman LH, Foord AJ, Pritchard LI, Taylor TK, Selleck PW, Johnson MA, Sirega A, Poermadjaja, Daniels PW. 2007. Indonesia veterinary laboratory capacity building project for highly pathogenic avian influenza. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Gibbs SEJ. 2007. West Nile Virus - experiences in North America, lessons for Australia? Wildlife Disease Association (Australasian Section) Annual Conference "Health monitoring and disease investigation in population management and species recovery programs". Dryandra Woodland, WA. The Conference.

Gillespie, M. J. 2007 Gene expression in the lactating pigeon crop Burwood, Vic. Deakin University

Gubala A, Davis S, Weir R, Proll D, Barnard RT, Melville L, Boyle DB. 2007. Characterization of Australian Rhabdoviruses isolated from insects and animals. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Gubala A, Davis S, Weir R, Proll D, Barnard RT, Melville L, Boyle DB. 2007. Characterization of Australian Rhabdoviruses isolated from insects and animals. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Gudkovs N, Pradeep B, Stalin Raj V, Slater J, Sittidilokratna N, Mohan CV, Walker PJ. 2007. Application of PCR for improved shrimp health management in the Asian region. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade resort, Cairns, QLD. The Conference.

Guo P, Hinton TM, Thomas J, Lowenthal JW, Bean AGD. 2007. Conservation of Th1 therapeutic activities against viral immunosuppression in chickens. ASI Annual Scientific Meeting Manly 2007 Australasian Society for Immunology. Manly Pacific Sydney. The Meeting.

Halpin K, Heine HG, Johnson MA, Stevens V, Trinidad L, Davies K, Selleck PW. 2007. Development and consolidation of an EQU program for the molecular diagnosis of Avian Influenza. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Hammond JM. 2007. Production of FMDV diagnostic reagents to improve outbreak preparedness - Recombinant AGS. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Hancock T, Johnson DL, Klippel J, Middleton DJ. 2007. Animal husbandry and welfare progression in high biocontainment facility: a challenging mix. ANZLAA Conference Australian and New Zealand Laboratory Association Bridging the Gap. Holiday Inn, Adelaide. The Conference.

Heine HG, Foord AJ. 2007. Molecular diagnosis of Equine Influenza H3N8. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Heine HG, Gleeson LJ, Fusheng G, Sims L, Trinidad L, Lowther SL, Bingham J, Selleck PW. 2007. Identification of a novel hemagglutinin cleavage site in a highly pathogenic avian influenza from North Korea. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Higgins M, Carson J, Gudkovs N. 2007. Development of an improved identification matrix for Aeromonas Salmonicida. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Higgins M, Carson J, Gudkovs N. 2007. Development of an improved identification matrix for Aeromonas salmonicida. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Hinton TM, Mitter N, Mahoney T, Doran TJ. 2007. Development of a new generation Marek's disease virus vaccines. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Hyatt AD, Boyle DG, Olsen V. 2007. Detection of Bd: methods and recommendations. Amphibian declines and Chytridiomycosis: translating science into urgent action. Tempe, Arizona. The Conference.

Hyatt AD, Hayes D, Olsen V, Boyle DG. 2007. In search of viruses: an electron microscopical study. Devil Facial Tumour Disease Senior Scientist's Scientific Forum. Life Sciences Lecture Theatre, Sandy Bay Campus, University of Tasmania. The Forum.

Hyatt AD. 2007. Diagnostic Electron Microscopy: historical review and future. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Hyatt AD. 2007. Frogs and viruses. AVA Annual Conference. Melbourne Convention Centre, Melbourne. The Convention.

Hyatt AD. 2007. Opening Address. Australian Microbeam Analysis Society AMAS IX - 9th Biennial Symposium. Brighton Savoy, Brighton, Vic. The Symposium.

Hyatt AD. 2007. Successes and the future: a diagnostic perspective. Integrated Research Challenges in Environmental Biology Emerging Wildlife Diseases: threats to amphibian biodiversity. Arizona State University, Arizona, USA. The University.

Hyatt AD. 2007. Time for change: Future requirements for the study of infectious diseases and identification of infectious agents. AMAS IX The Ninth Biennial Symposium. Brighton Savoy, Brighton, Vic. Australian Microscopy and Microanalysis Society.

Jack PJM, Amos-Ritchie R, Reverter A, Pritchard LI, Palacios G, Briese T, Boyle DB. 2007. Microarray-based detection of viruses causing vesicular or vesicular-like lesions in livestock animals. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Jeggo MH. 2007. Labs of the future. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Johnson J, Durr PA, Robertson I, Fenwick S. 2007. Investigation of the ecology of live bird markets and their role in the epidemiology of avian influenza in Bali and Lombok. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Karpala AJ, Broadway MM, Lowenthal JW, Doran TJ, Bean AGD. 2007. Cellular responses to dsRNA are TLR3 dependent and can be modulated by type 1 interferon. TLROZ 2007 Pattern recognition receptors in immunity and disease. Melbourne. The Meeting.

Keyburn AL, Boyce JD, Vaz P, Bannam TL, Ford ME, Parker D, Rood JI, Moore RJ. 2007. NetB a novel Clostridium perfringens toxin that is an essential virulence factor for necrotic enteritis in chickens. BacPath9: the molecular biology of bacterial pathogens. Mantra Erskine

Beach Resort, Lorne, Vic. The Conference.

Keyburn AL. 2007. Overturning 30 years of dogma in poultry disease. CRCA Conference. Perth. The Conference.

Klippel J, Johnson DL, Hancock T, Middleton DJ. 2007. The happy ferret: a guide to procedural refinement. ANZLAA Conference Australian and New Zealand Laboratory Association Conference Bridging the Gap. Holiday Inn, Adelaide. The Conference.

Layton DS, Strom ADG, O'Neil TE, Broadway MM, Ierino FL, Bean AGD. 2007. Immunomodulation for Xenotransplantation. CSIRO Transformational biology workshop. CSIRO Discovery Centre, Canberra. The Workshop.

Lowther SL, Rockman S, Klippel J, Hancock T, Middleton DJ. 2007. Tissue localisation of A/Vietnam/1203/04 H5N1 in ferrets during acute disease. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Lunt RA, Linchongsubongkoch, Gleeson LJ, Abila R, Morrissy CJ, Leowijuk C, Edwards SF, Le Blanc Smith PM, Hammond JM. 2007. Advancing the role of a regional reference laboratory for Foot-and-Mouth disease in South East Asia. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Lunt RA, White JR, Newberry KM, Pourquier P, Comtet L, Whittle S. 2007 . Development of a commercial ELISA for the detection of serum antibody to Akabane virus. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Marsh GA, Rabadan R, Levine AJ, Palese P. 2007. Highly conserved regions of the Influenza A virus polymerase gene segments are critical for efficient vRNA packaging. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Mathe NA, Crameri GS, Shiell BJ, Michalski WP, Wilks C, Wang LF. 2007. Determination of the fusion protein cleavage site of Beilong virus and J virus. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel, St Kilda, Vic. The Workshop.

McColl KA, Corbeil S, Williams LM, Lancaster M, Crane MStJ. 2007. Abalone Ganglioneuritis - a transmission trial, and time-course study. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

McColl KA, Corbeil S, Williams LM, Lancaster M, Crane MStJ. 2007. Abalone Ganglioneuritis - a transmission trial and time course study. FRDC Scientific Meeting. Cairns, QLD. The Meeting.

McEachern JA, Bossart KN, Tachedjian M, Crameri GS, Zhu Z, Dimitrov DS, Broder CC, Wang

LF. 2007. Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Group.

McKimm-Breschkin JL, Selleck PW, Usman T, Johnson MA. 2007. Analysis of the sensitivity of H5N1 isolates from the South East Asian region to Oseltamivir and Zanamivir. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson Ma. 2007. Indonesian H5N1 viruses demonstrate decreased sensitivity to oseltamivir . Options for the Control of Influenza VI Conference. Metro Toronto Convention Centre, Ontario, Canada. The Conference.

Moore RJ, Tizard MLV. 2007. Determination of tumour origin via profiling the microRNA expression patterns. Devil Facial Tumour Disease Senior Scientist's Scientific Forum. Life Sciences Lecture Theatre, Sandy Bay Campus, University of Tasmania. The Forum.

Morrissy CJ, Long NT, Hammond JM, Wright L, Pritchard LI, Schafer DJ, Ha W, Goff W, Hoa DM, Johnson MA, Daniels PW. 2007. Development of an improved capability in support of national biosecurity for the surveillance and control of Foot-and-Mouth disease in cattle and pigs in Vietnam. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Morrissy CJ, McEachern JA, Colling A, Wright L, Long NT, Goff W, Hammond JM, Johnson MA, Crowther J, Hoa DM, Daniels PW. 2007. International validation of a new 3 ABC ELISA for FMD serology. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Morrissy CJ, Schafer DJ, Wright L, Hammond JM, Bingham J, Hong NTT, Neumann E, Middleton DJ, Goff W, Ha W, Jaros P. 2007. Development of Porcine Circovirus (PCV) diagnostic capability at AAHL allowing the detection and nucleotide sequence analysis of PCV from disease outbreaks. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Muller JD, Foord AJ, Heine HG, McEachern JA, Bossart KN, Yu M, Wilks C, Wang LF. 2007. Antigenicity studies and development of serological tests for Foot and Mouth Disease Virus. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Muller JD, Foord AJ, Heine HG, Yu M, Wilks CR, Wang LF. 2007. Development and evaluation of a recombinant antibody-based competitive ELISA for FMD. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Mungall BA, Middleton DJ, Eisen D. 2007. Plasma-derived mannose-binding lectin has in vitro activity against Henipa viruses. 1st Congress of the Society of Innate Immunity. Antalya, Turkey. The Congress.

Mungall BA, Middleton DJ, Halpin K, Daniels PW, Bingham J. 2007. Experimental models for Henipavirus infection: bats, cats and pseudo-rats. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Mungall BA, Schopman NCT, Lambeth LS, Doran TJ. 2007. Inhibition of Henipavirus infection by RNA interference. The 4th Scientific meeting of the Australian Virology Group. Fraser Island, QLD. The Group.

Newberry KM, Lunt RA, McColl KA, Chamberlain T. 2007. A virus neutralization test for the detection of antibody to Australian Bat Lyssavirus. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Pritchard LI, Foord AJ, Taylor TK, Axell A, Lunt RA, Hammond JM, Groocock C, Lauerman LH, Daniels PW. 2007. A review of training in molecular diagnostic techniques for Avian Influenza in South East Asia. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Retallick MAS, Bacic A, Colegate SM, Hoffmann P, Michalski WP. 2007. Identifying Candidate biomarkers of Tunicaminyluracil toxin exposure in rat serum using a toxicoproteomic approach. ComBio 2007 Combined Conference Abstracts. Sydney Convention and Exhibition Centre, Sydney. The Conference.

Schlogel LM, Picco A, Kilpatrick AM, Hyatt AD, Daszak P. 2007. Presence of Batrachochytrium dendrobatidis and amphibian ranaviruses in U.S. Markets. Amphibian declines and Chytridiomycosis: translating science into urgent action. Tempe, Arizona, USA. The Conference.

Selleck PW. 2007. Influenza. ASM 2007 Annual Scientific Meeting of the Australian Society for Microbiology. Adelaide Convention Centre, Adelaide. The Meting.

Shiell BJ, Tachedjian M, Vaughan JA, Beddome G, Farn JL, Michalski WP. 2007. Analysis of recombinant Phospholipase B from Moraxella Bovis with Anomalous Electrophoretic behavior. 4th International Peptide Symposium in conjunction with 7th Australian Peptide Conference and 2nd Asia-Pacific International Peptide Symposium. Cairns, Great Barrier Reef, QLD. The Symposium.

Smith CS, De Jong C, Crameri GS, McEachern JA, Yu M, Tachedjian M, Henning J, Meers J, Wang LF, Field HE. 2007. Investigation of SARS-like coronaviruses in Australasian bats. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease.

Novotel St Kilda, Vic. The Workshop.

Tachedjian M, Bulach D, Smith CS, De Jong C, Middleton DJ, Field HE, Wang LF. 2007. Molecular and immunological investigations of bat-virus interactions: sequencing the bat transcriptome. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

Thalmann C, Yu M, Barnard RT, Wang LF. 2007. Molecular characterisation of Broome virus. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel, St Kilda, Vic. The Workshop.

Tizard MLV, Cottee P, Glazov EA, Dalrymple BP, Moore RJ. 2007. Discovery and application of microRNAs in the chicken: a model system with an economic benefit. CSIRO Transformational biology workshop. CSIRO Discovery Centre, Canberra. The Workshop.

Tyrrell KL, White JR, McLure SJ, Lello J. 2007. Effects of dynamic 'communal' interactions on disease processes and individual agent diagnosis where multiple infectious agents are present in sheep. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Tyrrell KL, White JR. 2007. Development of a high throughput robotics-based ELISA for the detection of antibodies specific for parasite worm species in sheep. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Virtue ER, Marsh G, Purcell D, Wang LF. 2007. Identification of virulence factors for Henipavirus infection. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel, St Kilda, Vic. The Workshop.

Walker PJ. 2007. Emerging diseases and health management in aquaculture. Indaqua 2007. Chennai Trade Centre, Chennai, India. The Conference.

Wang LF, Yu M, Tachedjian M, Crameri GS, McEachern J.A. 2007. Role of receptor specificity in SARS-CoV emergence. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Wang LF. 2007. Bats, Civets and the emergence of SARS. 16th Combined Biological Sciences Meeting. UWA University Club, University of Western Australia, Perth. UWA.

Wang LF. 2007. Identification of infectious pathogens via molecular biological approaches. Devil Facial Tumour Disease Senior Scientist's Scientific Forum. Life Sciences Lecture Theatre, Sandy Bay Campus, University of Tasmania. The Forum.

Wang LF. 2007. Virus-host cell interaction. ASM 2007 Annual Scientific Meeting of the Australian Society for Microbiology. Adelaide Convention Centre, Adelaide. The Meeting.

Wang LF. 2007. Wildlife hosts of SARS-coronavirus and related viruses. 25th International Congress of Chemotherapy (ICC) and the 17th European Congress of Clinical Microbiology and Infectious Diseases (EUCCMID). Munich, Germany. The Congress.

Wang LF. 2007. Zoonotic viruses of bat origin - discovery and diagnosis. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade Melbourne. The Symposium.

White JR, Hewitson GR, McDonald TS, Hansson E, Heine HG, Foord AJ, Diallo IS. 2007. An evaluation of commercially available nucleic acid extraction methods for the processing and subsequent qPCR analysis of samples infected with Avian Influenza virus. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Wijegoonawardane PM, Cowley JA, Kiatpathomchai W , Nielsen L, Walker PJ. 2007. Natural recombination amongst genotypic variants of the yellow head virus complex and its implications for genotype assignment and pcr-based diagnostics. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Williams LM, Crane MStJ, Kort AB, Schuller KA, Ellis DC. 2007. Virus susceptibility of Southern Bluefin Tuna (Thunnus maccolyii) gonad and kidney cell lines. Third FRDC Aquatic Animal Health Subprogram Scientific Conference. The Rydges Esplanade Resort, Cairns, QLD. The Conference.

Wise TG, Doran TJ. 2007. Inhibition of avian influenza virus H5N1 using chicken RNA polymerase III shRNA vectors. 4th Scientific Meeting of the Australian Virology Group. Fraser Island, QLD. The Meeting.

Wong F, Lancaster M, Crane MStJ, Corbeil S, Hyatt AD, Tan J, Savin K, Cogan N, Sawbridge T, Warner S. 2007. Characterisation of the herpes-like virus infecting Australian populations of abalone Haliotis SPP. by whole genome pyrosequencing. WAVLD 2007 Preparing for the animal health challenges of the future: 13th International World Association of Veterinary Laboratory Diagnosticians Symposium: symposium proceedings. Crown Promenade, Melbourne. The Symposium.

Wong MH, Yaiw KC, Hyatt AD, Van Driel R, Eaton BT, Crameri SG, Wang LF, Ng ML, Devi S, Wong KT. 2007. Tioman and Menangle viruses infection in human neuronal, endothelial and African Monkey Kidney Cells. 6th ASEAN Microscopy Conference. Impiana Cherating Hotel, Pahang, Malaysia. The Conference.

Yaiw KC, Bingham J, Crameri GS, Mungall BA, Hyatt AD, Eaton BT, Shamala D, Wang LF, Wong KT. 2007. Experimental Tioman virus infection in pigs. 24th World Congress of pathology and Laboratory Medicine Meeting the challenges of globalisation and miniaturisation. Sunway Pyramid Convention Centre Petaling Jaya, Selangor, Malaysia. The Congress.

Yu M, Tachedjian M, McEachern JA, Crameri GS, Selleck K, Field HE, Wang LF. 2007. Functional analysis of bat ACE2 molecules on engineered HELA cell surface as receptor for SARS-COV. Annual National Workshop Australian Biosecurity CRC for Emerging Infectious Disease. Novotel St Kilda, Vic. The Workshop.

(B) Human Protection and Performance Division, Defence Science Technology Organisation (DSTO)

The policy of the Defence Science and Technology Organisation is to publish results of a general scientific value in the open literature. Information that is more specialised and relevant particularly to defence is published in laboratory reports, which are unclassified and available to the public, unless they contain information that might prejudice the security of Australia or information that is commercial-in-confidence. It is envisaged that all results of the biological research will be either unclassified or "commercial-in-confidence".

The Defence Health Services Division encourages the publication of scientific reviews of the literature in the biological defence area. Over the past 12 months, several articles have been published or accepted for publishing in the Australian and international scientific literature. These include:

Liu, C.Q., Tran, H., Alderton, M.R. Nuttall, S.D., Wilkins, M., Streltsov, V.A., Construction, crystal structure and application of a recombinant protein that lacks the collagen-like region of BclA from Bacillus anthracis spores, Biotechnology and Bioengineering July 2007 (in press).

Dawson, R., Liu, C.Q. Properties and Applications of Antimicrobial Peptides in Biodefence Against Biological Warfare Threat Agents, Critical Reviews in Microbiology Oct 2007.

Dorsch, M., Gauci, P., Gubala, A., McAllister, J., Pickering, A., Ramasamy, S., Sait, M., Advances in Anaphylaxis and Treatment of Potential Biological Warfare Agents: A Review of the Open Publications for 2005 and 2006. DSTO Report June 2007.

Hartley, P.G., Alderton, M.R., Dawson, R.M. and Wells, D. 2007, Ricin antitoxins based on lyotropic mesophases containing galactose amphiphiles. *Bioconjugate Chemistry* 18, 152-159.

McAnoy, A.M., Sait, M. and Pantelidis, S. 2007, Establishment of a Vaporous Hydrogen Peroxide Bio-Decontamination Capability. DSTO-TR-1994.

McDowall, L. 2007, Design of Polymers for the Neutralisation of the Plant Toxin Ricin. DSTO-DP-1103.

Polyzos, A., Alderton, M., Dawson, R.M. and Hartley, P.G. 2007, Bio-functionalized surfactant mesophases as polyvalent inhibitors of cholera toxin. *Bioconjugate Chemistry* 18, 1442-1449.

Ross S. and Dawson R.M. 2007, Advances in treatment of chemical agent poisoning: review of the open scientific literature 2006. DSTO-DP-1099.

Sait, M., McAnoy, A.M., Jamriska, M, Pantelidis, S. and Alderton, M.R. 2007, Detection of aerosolised Geobacillus stearothermophilus spores during Australia Post mail-processing operations. DSTO-CR-2007-0329.

Sait, M., Lewis, J., Pantelidis, S., Peeler, J. and Blackman, L. 2007, Evaluation of the RAZOR PCR instrument for the detection of Ricin. DSTO-CR-2007-0330.

Tran, H. and Liu, C.Q. 2007, Rapid Detection of Ricin by Surface Plasmon Resonance. DSTO-TR-2021.

Tran, H. and Liu, C.Q. 2007, Evaluation of M1M Ricin Detection Kits. DSTO-CR-2007-0071.

Tran, H. and Liu, C.Q. 2007, Evaluation of M1M botulinum neurotoxins A and B detection kits. DSTO-CR-2007-0142.

Tran, H., Leong, C., Loke, W.K., Dogovski, C., Liu, C.Q. 2007, Surface Plasmon Resonance Detection of Ricin and Horticultural Ricin Variants in Environmental Samples, Toxicon.

(C) The National High Security Laboratory (NHSQL)

The National High Security Laboratory (NHSQL) operates under the auspices of the Victorian Infectious Diseases Reference Laboratory (VIDRL). The laboratory only carries out a limited number of research activities that result in publication.

Gustavo Palacios, Druce J, Du L, Tran T, Birch C, Briese T, Conlan S, Phenix-Lan Q, Hui J, Marshall J, Simons J F, Egholm M, Paddock, C.D. M.P.H.T.M, Sun-Ju S, Goldsmith C.S, Zaki S. R, Catton M, Lipkin M.D. A New Arenavirus in a Cluster of Fatal Transplant-Associated Diseases. N.Engl Med 2008;358 p1-8

CONFIDENCE BUILDING MEASURE D *[FormD]*

Active promotion of contacts

Australia's submissions with respect to the information sought under Form D (Part 1a-g) and Form D (Part 2) are at **Attachments 5.1** and **5.2**, respectively.

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

   For each such event, the following information should be provided:

   a. name of the conference, etc. .....

   b. arranging organization(s), etc. .....

   c. time .....

   d. place .....

   e. main subject(s) for the conference, etc. .....

   .....

   f. conditions for participation .....

   .....

   g. point of contact for further information, registration, etc. .....

   .....

   .....

2. Information regarding other opportunities

   .....

   .....

   .....

Attachment 5.1

CONFIDENCE BUILDING MEASURE D *[Form D, part 1]*

Active promotion of contacts

Australia welcomes *bona fide* professional contact with other researchers in matters directly related to the Biological Weapons Convention. Contact should be made with the facility described in Form A, part 2 (iii).

1. Planned international conferences, symposia, seminars, and other similar fora in which Australia participated in 2007

BWC Regional Workshops, including specialised regional workshops on biosafety and biosecurity, have been convened to help BWC States Parties in South East Asia become better engaged with the Geneva-based intersessional program of work and related activities as a means to reduce the possibility of bioterrorism in the region, or the inadvertent assistance by states in the region to biological weapons programs being developed elsewhere.

DSTO is a contributing member of the Technical Cooperation Program (TTCP) CBD Group, and through a CBR MOU with Canada, US and the UK collaborates in matter directly relating to Biological Defence

Attachment 5.2

CONFIDENCE BUILDING MEASURE D *[Form D, part 2]*

Active promotion of contacts

2. Information regarding other opportunities

CONFIDENCE BUILDING MEASURE E *[Form E]*

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and mens of delivery specified in Article I	Yes	Yes	No	Yes
(b) Exports of micro-organisms* and toxins	Yes	Yes	Yes	No
(b) Imports of micro-organisms* and toxins	Yes	Yes	No	No

In addition to the above summary, an overview of key Australian Government legislation relevant to the BWC is provided below:

Background

Australia has the following Australian Government legislation, regulations and other measures to declare under this confidence-building measure. Australia has taken a range of legislative and executive measures that ensure compliance with the UN Security Council Resolution 1540 (2004).

Australia is fully committed to the work of the 1540 Committee in ensuring global implementation of this resolution. As well as WMD-dedicated legislation, there is a considerable amount of health, safety and environmental legislation that control access to hazardous biological materials. The Australian Government is reviewing all WMD and hazardous materials controls, with a view to enhancing them if necessary for counter-terrorism purposes.

***Chemical Weapons (Prohibition) Act 1994* and associated regulations**

This Act, administered by the Australian Safeguards and Non-Proliferation Office within the Department of Foreign Affairs and Trade, gives effect to Australia's obligations to the

Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction. The Act controls certain chemicals which may be used as weapons, including the natural toxins ricin and saxitoxin. The Act's general purpose criterion also applies to the hostile use of any chemical, including other toxins.

The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Declaration of legislation, regulations and other measures

Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction. The Act controls certain chemicals which may be used as weapons, including the natural toxins ricin and saxitoxin. The Act's general purpose criterion also applies to the hostile use of any chemical, including other toxins. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Act 1976

This Act, which is administered by the Attorney-General, makes it unlawful for Australians to develop, produce, stockpile or otherwise acquire or retain microbial or other biological agents or toxins whatever their origin or method of production, of types and in quantities that have no justification for prophylactic, protective or other peaceful purposes; or weapons, equipment or means of delivery designed to use such agents or toxins for hostile purposes or in armed conflict. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Regulations 1980

These Regulations specify the way in which substances acquired under the Act should be stored, disposed of and analysed.

Customs Act** 1901* and ***Customs (Prohibited Exports) Regulations

Under the *Customs Act 1901*, the *Customs (Prohibited Exports) Regulations 1958* prohibits the exportation from Australia of defence and dual-use goods listed in the 'Defence and Strategic Goods List' (DSGL) without prior permission from the Minister for Defence or an authorised person. Under the regulations, the Minister for Defence may authorise in writing a person employed in the Department of Defence to approve exports of defence and dual-use goods listed on the DSGL. Applications to export goods listed in the DSGL are considered on a case-by-case basis against published policy criteria to ensure exports of defence and dual-use goods are consistent with Australia's broader national interests and international obligations.

The DSGL is divided into two parts: Part 1 of the DSGL covers defence and related goods, which are those goods and technologies designed or adapted for use by armed forces or goods that are inherently lethal. Part 2 of the DSGL covers those goods that have a dual use. Dual-use goods comprise equipment and technologies developed to meet commercial needs, but which

may be used either as military components or for the development or production of military systems or weapons of mass destruction. As such, Part 2 includes human pathogens and toxins, animal pathogens, plant pathogens and equipment capable of being used to develop biological weapons.

The DSGL is amended from time to time to reflect changes in the various multilateral non-proliferation and export control regimes of which Australia is a member.

National Health Security Act 2007

The *National Health Security Act* was passed by the Australian Parliament in September 2007. It has two main operative parts; Part 2 of the Act enacts Australia's responsibilities under the International Health Regulations 2005 and formalises surveillance systems in Australia, while Part 3 establishes a regulatory scheme for biological agents of security concern. Part 3 of the Act enables a national authority (based in the Department of Health and Ageing) to regulate organisations that handle security sensitive biological agents. The Act establishes a list of agents to be regulated, a national register that is informed by mandatory reporting, purposes for which the agents may be handled, security (physical, personnel and transport) standards that must be met while handling agents, exemptions from regulation, and an inspection and auditing scheme to monitor compliance with the regulatory scheme.

Quarantine Act 1908 and associated regulations

The *Quarantine Act 1908* is designed to prevent the introduction of serious pests and diseases affecting humans, plants and animals into Australia. Accordingly, in conjunction with the *Biological Control Act* (see below), it controls the import into Australia of all biological material and may prohibit the import in some circumstances.

Responsibility for human quarantine is administered by the Minister for Health and Ageing through this Act. Responsibility for plant and animal quarantine is administered by the Minister for Agriculture, Fisheries and Forestry through this Act. All biological agents require prior permission to import. Under the provisions of section 13 of the Act, goods of biological origin, including human pathogenic microorganisms and toxins, may only be imported into Australia if approval has been given by a Director of Quarantine (Animal/Plant or Human). In giving approval, the Director may require that the importer adhere to certain conditions or requirements, including, but not limited to, the storage, transportation, distribution and disposal of the goods, the use to which the goods may be put, and the personnel authorised to handle or use the goods.

Import conditions vary depending on the nature of the organisms, and on the risks involved. High risk organisms such as serious pathogens of humans, animals and plants which might be considered as potential biological weapons would only be permitted under the most stringent, high security conditions. Very few such imports are approved, and generally those would be for diagnostic research in preparation for emergency responses to specific serious exotic disease incursions.

Penalties for the importation of controlled goods without a permit, and for breaches of permit requirements, are severe and may include a fine, imprisonment or both.

Biological Control Act 1984 and associated regulations

This Act is administered jointly by the Bureau of Rural Sciences and the Agriculture Industry Division of the Department of Agriculture, Fisheries and Forestry within the framework of the Federal Government's quarantine policy. It provides powers additional to those of the Quarantine Act in order to regulate the release of biological agents for the control of pests, diseases and weeds. It primarily covers issues of compensation for the release of a biological control agent.

Gene Technology Act 2000 and associated regulations

The object of this Act is to protect the health and safety of people and the environment from risks posed by, or as a result of, gene technology by identifying those risks and managing them by regulating certain dealings with genetically modified organisms (GMOs). Dealings include manufacturing, importing or conducting experiments with GMOs and require authorisation under legislation. In addition, there are legislative provisions for accreditation of organisations, certification of facilities and extensive monitoring and enforcement powers.

Therapeutic Goods Act 1989 and associated regulations

The Therapeutic Goods Administration of the Department of Health and Ageing regulates therapeutic goods for human use under this Act. The Act covers the import, manufacture, supply and export of therapeutic goods and includes pathogenic microorganisms where these are included in vaccines for human use.

Prior to initial supply for human use products must be entered in the Australian Register of Therapeutic Goods. Vaccines are registrable products and undergo evaluation by the Therapeutic Goods Administration prior to entry in the Register.

Weapons of Mass Destruction (Prevention of Proliferation) Act 1995 and associated regulations

The Act is administered by the Department of Defence and complements the existing controls contained in the *Customs Act 1901* and the *Customs (Prohibited Exports) Regulations*. The WMD Act and the associated Regulations provide the legislative basis for controlling the movement of goods and services that will or may assist in the development of a WMD program. It prohibits the supply or export of goods, not otherwise controlled by the *Customs Act*, or the provision of services, in circumstances where the goods or services may be used to assist in the development, production, acquisition or stockpiling of WMD, including biological weapons or their delivery systems. The prohibitions under the legislation apply where the person involved knows or suspects the connection with a WMD program, including a biological weapons program.

The Act applies extraterritorially as well as within Australia, covering the activities of Australian citizens or residents, as well as bodies incorporated in Australia. It provides a mechanism for

exporters to obtain written guidance from the Government on the risk of a particular planned transaction contributing to a biological weapons program.

Guidelines to prevent the inadvertent supply of biological weapons-applicable plant, equipment source cultures and expertise

The Guidelines are a non-statutory, non-proliferation measure, developed by the Department of Foreign Affairs and Trade, to raise the awareness of industry and researchers about the risk of inadvertent involvement in the biological weapons programs of other countries. The Guidelines have been circulated to biological industry, universities, relevant professional associations and government agencies.

CONFIDENCE BUILDING MEASURE F *[Form F]*

Declaration of past activities in offensive and/or defensive biological research and development programmes

In addition to the following information, see **Attachment 6** for explanation of research related to biological warfare defence in Australia.

1. Date of entry into force of the Convention for the State party.

   5 October 1977

2. Past offensive biological research and development programmes:

   - YES – NO

     No

   - Period(s) of activities
     Not applicable

   - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

     Not applicable, but see Attachment 6.

3. Past defensive biological research and development programmes:

   - YES – NO
     No

   - Period(s) of activities
     No, but see Attachment 6.

   - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

     No, but see Attachment 6.

Attachment 6

CONFIDENCE BUILDING MEASURE F *[Form F]*

Declaration of past activities in offensive and/or defensive biological research and development programmes

EXPLANATORY STATEMENT
RESEARCH AND DEVELOPMENT PROGRAMS RELATED TO BIOLOGICAL WARFARE AND DEFENCE IN AUSTRALIA SINCE 1 JANUARY 1946

Between 1946 and 1994, Australia had no R&D program specifically aimed at defence against biological and toxin weapons. However, some methods for protection against chemical warfare agents could also be used to protect against biological agents. As Australia has had a longstanding R&D program to develop protection against chemical agents, it had, though only incidentally, also been involved in the development of means capable of offering some protection from biological weapons.

The Position at the end of World War II

During World War II, Australia acquired a protective capability against chemical and biological warfare (CBW), which included the equipping of military units with protective clothing, respirators, detection apparatus and decontamination equipment. This capability was associated with the threat of chemical warfare, as almost all of the major combatants possessed chemical weapons.

Australia had no biological weapons and knew little about them. While a need for some defence against them was generally perceived, no major specific steps were taken to achieve this. The tendency was to regard chemical and biological weapons as a single category of threat, with biological weapons treated as the lesser element.

The Situation from 1945 to the 1970s

In the late 1940s and 1950s Defence committees assessed the need for defence against biological agents. The view adopted was that if biological threats arose, Defence authorities would co-opt staff from public health facilities who were trained in microbiology and biological sciences.

In this Australia received limited information on biological defence from the United States of America, the United Kingdom and Canada through the Technical Cooperation Program (TTCP). Under TTCP, there is provision for collaborative research on biological defence, but Australia never participated in that research.

During the 1960s and 1970s some research was conducted in an Australian Defence laboratory on toxins and venoms from Australian animals and plants. The research had no biological warfare focus, and was undertaken solely for the purpose of developing expertise in toxicology. The results of the research were published in scientific journals, contributing to the open scientific literature.

Declaration of past activities in offensive and/or defensive biological research and development programmes

The Situation from 1970 to 1994

During this period the policy was to maintain a watching brief on developments in biological warfare defence research so that a competency could be maintained to advise on policy and to give direction to training for the Australian Defence Force. This competency was derived from open literature and from Australia's partners under The Technical Cooperation Program (TTCP). No research on defence against toxins (or other biological warfare agents) was undertaken during this period.

Australia did, however, maintain an R&D program into chemical defence and the protective aspects of this program and some incidental common utility in biological defence.

1994 – Present

In 1994, it was recognised that Australia's knowledge of toxins as warfare agents needed to be strengthened if appropriate advice on defensive measures was to be given to the Australian Defence Force and in support of the country's arms control objectives. Consequently, the Government gave approval to commence a modest program of Research into defence against toxins as warfare agents.

It was also recognised that the Government needed advice on defence against biological weapons if it was to pursue its aims of strengthening the Biological Weapons Convention. Consequently, the policy of maintaining only a watching brief on BW defence research was modified to allow research in BW defence that did not involve pathogenic reproducing organisms. Such activities as epidemiological studies, computer simulations and studies of the detection of toxins could then be undertaken.

In 1998, government approval was given for DSTO to undertake biological defence work with reproducing organisms up to Risk Group 3, with interdepartmental oversight of all such activities. This research allows Australia to play a larger part in those TTCP Panels that deal with BW defence research and obtain access to more information held by our cooperative partners. Australia still maintains its active program into researching protective aspects of defence against chemical agents and has expanded the scope to include defence against biological weapons (e.g. incorporation of antibacterials in carbon adsorbents).

CONFIDENCE BUILDING MEASURE G *[Form G]*

Declaration of vaccine production facilities

CSL is the primary manufacturer licensed by the Australian Government pursuant to the *Therapeutic Goods Act 1989* to produce vaccines for the protection of humans included on the Australian Register of Therapeutic Goods (ARTG). The licence requires the manufacturer to comply with principles of Good Manufacturing Practice.

1. Name of facility:

CSL Limited

2. Location (mailing address):

45 Poplar Road
Parkville Victoria 3052
Australia

3. General description of the types of diseases covered:

Vaccine products must be entered in the Australian Register of Therapeutic Goods prior to supply of the products for human use. Registered products manufactured by CSL Limited are:

Diphtheria Vaccine
Diphtheria & Tetanus Vaccine
Influenza Vaccine
Plague Vaccine
Q fever Vaccine
Tetanus Toxoid Vaccine
Triple Antigen (Diphtheria, Tetanus, Pertussis)
Cholera Vaccine
Typhoid Vaccine
*Malarial Vaccine

* CSL manufactures the Malarial Vaccine for another sponsor, for export to Papua New Guinea only.

Note that Section 3, General Description of the Types of Diseases Covered, CSL Limited sponsor the following vaccines according to the Australian Register of Therapeutic Goods (ARTG):

Cholera Vaccine
Diphtheria and Tetanus Vaccine

Declaration of vaccine production facilities

Diphtheria Vaccine
Influenza Vaccine
Meningococcal Vaccine
Tetanus Toxoid Vaccine
Triple Antigen (Diphtheria, Tetanus, Pertussis)
Diphtheria, Tetanus, Pertussis and Hepatitis B Vaccine
Typhoid Vaccine
Q Fever Vaccine
Plague Vaccine
Yellow Fever Vaccine
Rotavirus Vaccine
Human Papilloma Virus Vaccine
Japanese Encephalitis Vaccine
Rabies Vaccine
Measles, Mumps, Rubella Vaccine
Measles, Mumps, Rubella, Varicella Vaccine
Rubella Vaccine
Varicella Vaccine
Hepatitis A Virus Vaccine
Hepatitis B Virus Vaccine
Haemophilus Influenzae Type B and Hepatitis B Virus Vaccine

There are other manufacturers in Australia with a GMP licence issued by the TGA to produce biological goods – this category includes, but is not limited to, vaccines. The list of these facilities may be accessed from the TGA on-line services home page at www.tgasime.health.gov.au and by selecting the link to "Australian Manufacturers Database". The relevant manufacturers may be located by searching for appropriate terms, for example "biological" or "vaccines". CSL may use one or more of such GMP-licensed manufacturers to supply components of its vaccines.

A search for the word "vaccines" identifies two additional manufacturers:

- Queensland Institute of Medical Research has been issued with a license that is restricted to the manufacture of clinical trial autologous vaccines for melanoma.

- Ludwig Institute for Cancer Research has been issued with a license that authorises quality control testing, packaging & labelling, & release for supply of peptide vaccines, monoclonal antibodies, recombinant proteins & other clinical trial products.

Neither of these manufacturers is listed on the ARTG as sponsors of vaccines (i.e. responsible for the commercial supply).